

Center for Vaccine  
Ethics and Policy



**Vaccines and Global Health: The Week in Review**  
**27 February 2021 :: Issue 596**  
**Center for Vaccine Ethics & Policy (CVEP)**

*This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.*

*Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted and the elements of each edition are presented as a set of blog posts at <https://centerforvaccineethicsandpolicy.net>. **This blog allows full text searching of over 21,000 entries.***

*Comments and suggestions should be directed to*

*David R. Curry, MS*

*Editor and*

*Executive Director*

*Center for Vaccine Ethics & Policy*

*[david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)*

**Request email delivery of the pdf:** *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org).*

**Support this knowledge-sharing service:** *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

**Contents** *[click on link below to move to associated content]*

A. [Milestones :: Perspectives :: Featured Journal Content](#)

B. [Emergencies](#)

C. [WHO; CDC \[U.S., Africa, China\]](#)

D. [Announcements](#)

E. [Journal Watch](#)

F. [Media Watch](#)

## ***Milestones :: Perspectives :: Research***

### ***Editor's Note:***

As is obvious to all, the sheer volume of strategic announcements, regulatory actions, country program decisions, commentary, and, indeed, misinformation around COVID response continues at extraordinary levels. Our weekly digest strives to present a coherent and comprehensive snapshot, but cannot be exhaustive. If you recognize a missed strategic development, a new source of rigorous analysis, or an insight/commentary that would benefit our common understanding, please advise me...we will review suggestions and consider inclusion in a subsequent edition:

[david.r.curry@ge2p2global.org](mailto:david.r.curry@ge2p2global.org)

.....  
.....

## **Immunization Agenda 2030**

**New dedicated website:** [www.immunizationagenda2030.org](http://www.immunizationagenda2030.org)

On the website you will find:

- :: IA2030 Vision and Strategy in all six UN languages
- :: Strategic Priority technical annexes (translation available shortly)
- :: Core Principle annexes (translation available shortly)
- :: IA2030 Framework for Action
- :: Other IA2030 annexes and companion documents

Important work is now ongoing to finalise a Monitoring and Evaluation (M&E) Framework and an Ownership & Accountability mechanism for IA2030.

A key effort is also underway to prepare for the IA2030 launch planned to take place in the run up to World Immunization Week in April and WHA in May.

.....  
.....

## **COVAX – Ghana, Cote Ivoire**

### **[COVID-19 vaccine doses shipped by the COVAX Facility head to Ghana, marking beginning of global rollout](#)**

*Press release 02/24/2021*

- :: COVAX announces 600,000 doses of the AstraZeneca/Oxford vaccine licensed to Serum Institute of India have arrived in Accra, Ghana; further deliveries to Abidjan, Cote d'Ivoire are expected this week
- :: Final first round of allocations for doses of AstraZeneca/Oxford and Pfizer-BioNTech vaccines, to the majority of countries and economies participating in the COVAX Facility, anticipated to be published in the coming days
- :: Beginning of global rollout means that, as readiness criteria are met and doses produced, vaccines will be shipped to Facility participants on a rolling basis

GENEVA/NEW YORK/OSLO, 24 February 2021 – Today, Ghana became the first country outside India to receive COVID-19 vaccine doses shipped via the COVAX Facility. This is a historic step towards our

goal to ensure equitable distribution of COVID-19 vaccines globally, in what will be the largest vaccine procurement and supply operation in history. The delivery is part of a first wave of arrivals that will continue in the coming days and weeks.

On 23 February, COVAX shipped 600,000 doses of the AstraZeneca/ Oxford vaccine, from the Serum Institute of India (SII) from Pune, India to Accra, Ghana, arriving on the morning of 24 February. The arrival in Accra is the first batch shipped and delivered in Africa by the COVAX Facility as part of an unprecedented effort to deliver at least 2 billion doses of COVID-19 vaccines by the end of 2021...

.....

### **Ghana becomes recipient of historic first shipment of COVAX vaccine**

*Statement by UNICEF Representative in Ghana, Anne-Claire Dufay and WHO Representative to Ghana, Dr Francis Kasolo on the arrival of the first COVID-19 vaccines in Accra*

ACCRA, 24 February 2021 – “After a year of disruptions due to the COVID-19 pandemic, with more than 80,700 Ghanaians getting infected with the virus and over 580 lost lives, the path to recovery for the people of Ghana can finally begin.

“This is a momentous occasion, as the arrival of the COVID-19 vaccines into Ghana is critical in bringing the pandemic to an end. The only way out of this crisis is to ensure that vaccinations are available for all. We thank all partners that are supporting the COVAX Facility to deliver safe and effective COVID-19 vaccines to all countries quickly and fairly.

“These 600,000 COVAX vaccines are part of an initial tranche of deliveries of the AstraZeneca / Oxford vaccine licensed to the Serum Institute of India, which represent part of the first wave of COVID vaccines headed to several low and middle-income countries.

“The shipments also represent the beginning of what should be the largest vaccine procurement and supply operation in history. The COVAX Facility plans to deliver close to 2 billion doses of COVID-19 vaccines this year. This is an unprecedented global effort to make sure all citizens have access to vaccines.

“We are pleased that Ghana has become the first country to receive the COVID-19 vaccines from the COVAX Facility. We congratulate the Government of Ghana – especially the Ministry of Health, Ghana Health Service, and Ministry of Information - for its relentless efforts to protect the population. As part of the UN Country Team in Ghana, UNICEF and WHO reiterate our commitment to support the vaccination campaign and contain the spread of the virus, in close cooperation with all partners, including Gavi and the Coalition for Epidemic Preparedness Innovations (CEPI)...

.....  
.....

### **COVAX – Injury Compensation**

#### **No-fault compensation programme for COVID-19 vaccines is a world first**

*:: New programme makes compensation available to eligible individuals in 92 low- and middle-income countries without need to resort to law courts*

*:: This is the first and only global vaccine injury compensation mechanism*

*:: The programme is funded by a small levy on each dose supported by the Gavi COVAX AMC*  
22 February 2021

The World Health Organization (WHO) and Chubb Limited (NYSE: CB), through ESIS Inc., a Chubb company, signed an agreement on behalf of the COVAX Facility on 17 February 2021 for the administration of a no-fault compensation programme for [the 92 low- and middle-income countries and economies eligible for support via the Gavi COVAX Advance Market Commitment \(AMC\) of the COVAX Facility](#).

As the first and only vaccine injury compensation mechanism operating on an international scale, the programme will offer eligible individuals in AMC-eligible countries and economies a fast, fair, robust and transparent process to receive compensation for rare but serious adverse events associated with COVAX-distributed vaccines until 30 June 2022.

By providing a no-fault lump-sum compensation in full and final settlement of any claims, the COVAX programme aims to significantly reduce the need for recourse to the law courts, a potentially lengthy and costly process.

ESIS, as the independent administrator of the programme, was selected in accordance with WHO's procurement rules and procedures, and charges no fees to applicants.

All vaccines procured or distributed through the COVAX Facility receive regulatory approval or an emergency use authorization to confirm their safety and efficacy.

But, as with all medicines, even vaccines that are approved for general use may, in rare cases, cause serious adverse reactions.

"The unprecedented nature of the COVID-19 pandemic has been matched by the largest ever rollout of new vaccines under the ACT-Accelerator and its vaccines pillar, COVAX. This no-fault compensation mechanism helps to ensure that people in AMC-eligible countries and economies can benefit from the cutting-edge science that has delivered COVID-19 vaccines in record time," said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. "We are pleased to be collaborating with Chubb, which has the capabilities to support the COVAX facility through its global network and claims handling ability. WHO's agreement with Chubb offers further protection and confidence in the life-saving power of vaccines."

"The No-Fault Compensation fund is a massive boost for COVAX's goal of equitable global access to vaccines: by providing a robust, transparent and independent mechanism to settle serious adverse events it helps those in countries who might have such effects, manufacturers to roll out vaccines to countries faster, and is a key benefit for lower-income governments procuring vaccines through the Gavi COVAX AMC," said Dr Seth Berkley, CEO of Gavi.

The COVAX no-fault compensation programme will be operationalized through its web portal ([www.covaxclaims.com](http://www.covaxclaims.com)) by 31 March 2021, which will include resources such as the programme's protocol, Frequently Asked Questions (FAQs) and information on how to submit an application.

Eligible individuals may apply for compensation under the programme once the portal becomes operational, even if a COVAX-distributed vaccine is administered to them before 31 March 2021.

The programme is financed initially through Gavi COVAX AMC donor funding, calculated as a levy charged on all doses of COVID-19 vaccines distributed through the COVAX Facility to the AMC eligible economies until 30 June 2022.

WHO is working with Chubb to secure insurance coverage for the programme with Chubb as lead insurer...

#### *About ESIS, a Chubb company*

ESIS, Inc. provides claim and risk management services to a wide variety of commercial clients. Our innovative best-in-class approach to program design, integration, and achievement of results aligns with the needs and expectations of our clients' unique risk management needs. With more than 66 years of experience and offerings in both the U.S. and globally, ESIS provides one of the industry's broadest selections of risk management solutions covering both pre- and post-loss services.

.....

#### **COVAX: Vaccine Supply**

##### **[UNICEF signs COVID-19 vaccine supply agreement with AstraZeneca](#)**

COPENHAGEN/NEW YORK, 25 February 2021 – UNICEF and AstraZeneca this week signed a long-term agreement for the supply of COVID-19 Vaccine AstraZeneca on behalf of the COVAX Facility.

Through the supply agreement, UNICEF, along with procurement partners including the Pan-American Health Organization (PAHO), will have access to up to 170 million doses of vaccines for around 85 countries. This is the third such agreement for COVID-19 vaccines, following previously announced agreements with Pfizer and the Serum Institute of India.

The AstraZeneca/Oxford vaccine received WHO Emergency Use Listing (EUL) on 15 February...

.....  
.....

#### **Coronavirus [COVID-19] - WHO**

*Public Health Emergency of International Concern (PHEIC)*

<https://www.who.int/emergencies/diseases/novel-coronavirus-2019>

#### ***Weekly Epidemiological and Operational updates***

Last update: 23 January 2021

**Confirmed cases** :: 113 076 707 [week ago: 110 384 747] [two weeks ago: 107 838 255]

**Confirmed deaths** :: 2 512 272 [week ago: 2 446 008] [two weeks ago: 2 373 398]

**Countries, areas or territories with cases** :: 223

#### **[Weekly epidemiological update - 25 February 2021](#)**

*Overview*

This special edition is supplementary to the [23 February Weekly Epidemiological Update](#).

**In this edition, we provide working definitions for SARS-CoV-2 variants of interest and variants of concern and the associated actions WHO will take to support Member States, their national public health institutes and reference laboratories, along with the recommended actions Member States should take.**



## WHO: Regulation and Prequalification

### Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process 24 Feb 2021

For 16 vaccine candidates, the presents Manufacturer, Name of Vaccine, NRA of Record, Platform, EOI Accepted Status, Pre-submission Meeting Held Status, Dossier Accepted for Review, Status of Assessment; Anticipated/Completed Decision Date

[click on the link above for full scale view]

#### Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process

	Manufacturer	Name of Vaccine	NRA of Record	Platform	EOI accepted	Pre-submission meeting held	Dossier accepted for review*	Status of assessment**	Anticipated decision date***
1.	BIONTECH	BNT162b2/COMIRNATY Tozinameran (INN)	EMA	Nucleoside modified mRNA	✓	✓	✓	Finalized	31/12/20
2.		AZD1222	Core – EMA Non-COVAX	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.	✓	✓	Accepted core data of AZ – non-Covax Data for Covax expected in March 2021	Non-Covax Core data. Awaited	NA March – April 2021
3.	AstraZeneca	AZD1222	MFDS KOREA	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.	✓	✓	✓	Finalized	15 Feb 2021
4.		Covishield (ChAdOx1_nCoV-19)	DCGI	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.	✓	✓	✓	Finalized	15 Feb 2021
5.		SARS-CoV-2 Vaccine (Vero Cell), Inactivated (InCoV)	NMPA	Inactivated, produced in Vero cells	✓	✓	✓	In progress	Earliest March
6.		SARS-CoV-2 Vaccine (Vero Cell), Inactivated	NMPA	Inactivated, produced in Vero cells	✓	✓	Additional expected end of Feb 2021		Earliest March
7.		mRNA-1273	EMA	mRNA-based vaccine encapsulated in lipid nanoparticle (LNP)	✓	✓	✓	In progress	Earliest March
8.		Ad26.COV2.S	EMA	Recombinant, replication-incompetent adenovirus type 26 (Ad26) vectored vaccine encoding the (SARS-CoV-2) Spike (S) protein	✓	✓	✓	In progress. Use abridged procedure relying on EMA	In March 3 – 5 days after EMA
9.		Sputnik V	Russian NRA	Human Adenovirus Vector-based Covid-19 vaccine	Additional information submitted	Several meetings held.	Rolling submission of clinical data started 09 Feb and additional data (CMC) still awaited.	Clinical review ongoing	Will be determined when CMC data is submitted
10.		Ad5-nCoV	NMPA	Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)	✓	✓	Rolling data starting April 2021		
11.			EMA	No pre-submission meeting yet.	Submitted EOI on 23 Feb	To be planned			
12.	Vector State Research Centre of Virology and Biotechnology	EpiVacCorona	Russian NRA	Peptide antigen	Letter received not EOI. Reply sent on 15/01/2021				
13.	Zhifei Longcom, China	Recombinant Novel Coronavirus Vaccine (CHO Cell)	NMPA	Recombinant protein subunit	Response to 2 <sup>nd</sup> EOI sent 29 Jan 2021. Additional information requested.				
14.	IMBCAMS, China	SARS-CoV-2 Vaccine, Inactivated (Vero Cell)	NMPA	Inactivated	Not accepted, still under initial development				
15.		Inactivated SARS-CoV-2 Vaccine (Vero Cell)	NMPA	No pre-submission meeting yet					

1. Beijing Bio-Institute of Biological Products Co-Ltd  
2. Wuhan Institute of Biological Products Co Ltd

\* Dossier Submission dates: more than one date is possible because of the rolling submission. Dossier is accepted for submission after screening of received submission

\*\* Status of assessment: 1. Under screening; 2. Under assessment; 3. Waiting responses from the applicant. 4. Risk-benefit decision 5. Final decision made

\*\*\* Anticipated decision date: this is only an estimate because it depends on when all the data is submitted under rolling submission and when all the responses to the assessors' questions are submitted.






## Our World in Data

### Coronavirus (COVID-19) Vaccinations

Our World in Data and the SDG-Tracker are collaborative efforts between researchers at the University of Oxford, who are the scientific editors of the website content; and the non-profit organization [Global Change Data Lab](#), who publishes and maintains the website and the data tools that make our work possible. At the University of Oxford we are based at the [Oxford Martin Programme on Global Development](#).



Research and data: Hannah Ritchie, Esteban Ortiz-Ospina, Diana Beltekian, Edouard Mathieu, Joe Hasell, Bobbie Macdonald, Charlie Giattino, and Max Roser

Web development: Breck Yunits, Ernst van Woerden, Daniel Gavrilov, Matthieu Bergel, Shahid Ahmad, Jason Crawford, and Marcel Gerber





**UNICEF COVID-19 Vaccine Market Dashboard :: Agreements Table Accessed 27 Feb 2021**

*An overview of information collected from publicly announced bilateral and multilateral supply agreements [Agreements view from 2021-02-15 to date]*

Number of vaccines approved for use <b>11</b>	Reported global vaccine production volumes in 2021 <b>19bn</b>	Number of secured vaccine doses <b>10.2bn</b>	Number of doses secured and optioned for the COVAX facility* <b>3.56bn</b>	Range of reported vaccine price per dose <b>\$2.19 - \$44</b>
--	---	--	---	--

Deal date	Recipient	Deal type	Vaccine name	Vaccine developer	Manufacturer
2021-02-15	Philippines	Government purchase	Sputnik V	Gamaleya Research Institute	Gamaleya Research Institute
2021-02-15	Philippines	Government purchase	Ad26 SARS-CoV-2	Janssen	Janssen
2021-02-15	Philippines	Government purchase	BNT-162	Pfizer/BioNTech	Pfizer/BioNTech
2021-02-16	Dominican Rep.	Government purchase	Covishield	AstraZeneca	Serum Institute of India
2021-02-16	Nepal	Government purchase	Covishield	AstraZeneca	Serum Institute of India
2021-02-17	Uzbekistan	Government purchase	Sputnik V	Gamaleya Research Institute	Gamaleya Research Institute
2021-02-17	European Commission	Multilateral purchase	mRNA-1273	Moderna	Moderna
2021-02-17	European Commission	Multilateral purchase	BNT-162	Pfizer/BioNTech	Pfizer/BioNTech
2021-02-18	COVAX	Multilateral purchase	NVXCoV-2373	Novavax	Novavax
2021-02-19	African Union	Multilateral purchase	Sputnik V	Gamaleya Research Institute	Gamaleya Research Institute
2021-02-19	Cambodia	Government purchase	Covishield	AstraZeneca	Serum Institute of India
2021-02-19	Sri Lanka	Government purchase	Covishield	AstraZeneca	Serum Institute of India

.....  
.....

**U.S.: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment**

**CDC - Coronavirus Disease 2019 (COVID-19) - Latest Updates**

:: [COVID Data Tracker](#) Friday, February 26, 2021



# COVID-19 Vaccinations in the United States

Overall US COVID-19 Vaccine | Deliveries and Administration; Maps, charts, and data provided by the CDC, updated daily by 8 pm ET<sup>†</sup>  
Represents all vaccine partners including jurisdictional partner clinics, retail pharmacies, long-term care facilities, Federal Emergency Management Agency and Health Resources and Services Administration partner sites, and federal entity facilities.

Total Vaccine Doses		People Vaccinated	Receiving 1 or More Doses	Receiving 2 Doses
Delivered	94,300,910	Total	47,184,199	22,613,359
Administered	70,454,064	% of Total Population	14.2%	6.8%
Learn more about the distribution of vaccines.		Population ≥ 18 Years of Age	47,143,403	22,598,904
		% of Population ≥ 18 Years of Age	18.5%	8.9%
		Read more about how these data are reported.		

CDC | Data as of: Feb 26 2021 6:00am ET | Posted: Feb 26 2021 12:24PM ET

## FDA

### [FDA Issues Emergency Use Authorization for Third COVID-19 Vaccine](#)

*Action Advances Fight Against COVID-19, Follows Comprehensive Evaluation of Available Safety, Effectiveness and Manufacturing Quality Information by FDA Career Scientists, Input from External Experts*

February 27, 2021

Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the third vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The EUA allows the Janssen COVID-19 Vaccine to be distributed in the U.S for use in individuals 18 years of age and older.

“The authorization of this vaccine expands the availability of vaccines, the best medical prevention method for COVID-19, to help us in the fight against this pandemic, which has claimed over half a million lives in the United States,” said Acting FDA Commissioner Janet Woodcock, M.D. “The FDA, through our open and transparent scientific review process, has now authorized three COVID-19 vaccines with the urgency called for during this pandemic, using the agency’s rigorous standards for safety, effectiveness and manufacturing quality needed to support emergency use authorization.” The FDA has determined that the Janssen COVID-19 Vaccine has met the statutory criteria for issuance of an EUA...

### [February 26, 2021 - FDA Statement on Vaccines and Related Biological Products Advisory Committee Meeting](#)

Following today’s positive advisory committee meeting outcome regarding the Janssen Biotech Inc. COVID-19 Vaccine, the U.S. Food and Drug Administration has informed the sponsor that it will rapidly work toward finalization and issuance of an emergency use authorization. The agency has also notified our federal partners involved in vaccine allocation and distribution so they can execute their plans for timely vaccine distribution...

## **White House [U.S.] *Briefing Room***

[Press Briefing by White House COVID-19 Response Team and Public Health Officials](#)

February 26, 2021 • Press Briefings

[FACT SHEET: 441 Federally-Supported Community Vaccination Centers in First Month of Biden-Harris Administration](#)

February 26, 2021 • Statements and Releases

[Remarks by President Biden at an Event Commemorating the 50 Millionth COVID-19 Vaccine Shot](#)

February 25, 2021 • Speeches and Remarks

[A Letter on the Continuation of the National Emergency Concerning the Coronavirus Disease 2019 \(COVID-19\) Pandemic](#)

February 24, 2021 • Statements and Releases

[Notice on the Continuation of the National Emergency Concerning the Coronavirus Disease 2019 \(COVID-19\) Pandemic](#)

February 24, 2021 • Presidential Actions

[Press Briefing by White House COVID-19 Response Team and Public Health Officials](#)

February 24, 2021 • Press Briefings

[FACT SHEET: President Biden Announces New Actions to Deliver Masks to Communities Hit Hard by the Pandemic](#)

February 24, 2021 • Statements and Releases

.....  
.....

## **Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment**

### **[News: Adapting COVID-19 vaccines to SARS-CoV-2 variants: guidance for vaccine manufacturers](#)**

CHMP, Last updated: 25/02/2021

EMA has issued guidance outlining the requirements for manufacturers planning to modify their COVID-19 vaccines in order to address coronavirus (SARS-CoV-2) variants.

Currently, three vaccines are authorised for use in the EU: Comirnaty, COVID-19 Vaccine Moderna and COVID-19 Vaccine AstraZeneca. Viruses typically mutate and several variant strains of SARS-CoV-2 have already been identified worldwide. The three authorised vaccines provide protection against the variants that are currently prevalent across Europe. However, it appears that with continued mutations and new variants emerging, authorised vaccines may need to be adapted, in time to ensure continued protection. Initial data indicates that some of these variants may have an impact on the level of protection provided by COVID-19 vaccines against infection and disease.

Therefore, it is an urgent public health priority to define an expedited regulatory process for the adaptation of vaccines to protect against current or future variants. There are ongoing discussions at international level on how to approach variants and vaccines in a coordinated way.

EMA's human medicines committee (CHMP) has adopted a reflection paper which details the laboratory (non-clinical), clinical, quality and manufacturing data needed to support the approval of such 'variant' vaccines.

The assumption behind the CHMP's guidance is that a new variant vaccine would largely rely on the same technology and platform as the 'parent' vaccine - a vaccine already approved in the EU for the prevention of COVID-19. The difference would be in the specific structure (antigen) selected to trigger the immune response in the body...

**[Reflection paper on the regulatory requirements for vaccines intended to provide protection against variant strain\(s\) of SARS-CoV-2 \(PDF/240.55 KB\) \(new\)](#)**

.....  
.....

### **Africa: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment**

*No new announcements identified.*

.....  
.....

### **Russia: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment**

**Russia: Sputnik V – “the first registered COVID-19 vaccine”**

<https://sputnikvaccine.com/newsroom/pressreleases/>

*Press Releases*

**[Sputnik V registered in countries with total population of over 1.1 billion people](#)**

Press release, 25.02.2021

**[Guatemala authorizes Sputnik V](#)**

Press release, 25.02.2021

**[Honduras authorizes Sputnik V](#)**

Press release, 24.02.2021

**[Egypt grants emergency use authorization for Sputnik V](#)**

Press release, 24.02.2021

**[Sputnik V approved in Guyana](#)**

Press release, 23.02.2021

**[Sputnik V registered in Kyrgyzstan](#)**

Press release, 23.02.2021

**[First batch of Sputnik V vaccine delivered to Mexico](#)**

Press release, 23.02.2021

.....

.....

## **China: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment**

### **Children aged 3-17 to be eligible for Sinopharm vaccine**

Chinese drugmaker Sinopharm said people aged 3 to 17 years old who are currently not included in the COVID-19 vaccine rollout will soon become eligible to receive inoculation...

Results from clinical trials involving the younger population have shown "no obvious differences" from trial data concerning those aged 18 to 59 years old, Liu said during an interview with China Central Television on Sunday.

"So we believe those aged 3 to 17 will soon be able to use the vaccines," he said...

### **NMPA grants conditional approval to CanSino's recombinant COVID-19 vaccine**

2021-02-27

The National Medical Products Administration (NMPA) conditionally approved the registration application of the recombinant COVID-19 vaccine (adenovirus type-5-vectored vaccine) developed by CanSino Biologics on Feb 25.

### **NMPA conditionally approves COVID-19 vaccine developed by Sinopharm's Wuhan institute**

2021-02-27

The National Medical Products Administration (NMPA) conditionally approved the registration application of the inactivated COVID-19 vaccine (Vero cell) developed by the Wuhan Institute of Biological Products administered by Sinopharm on Feb 25.

.....

.....

## **COVID Vaccine Developer Announcements**

### **Johnson & Johnson Single-Shot COVID-19 Vaccine Candidate Unanimously Recommended for Emergency Use Authorization by U.S. FDA Advisory Committee**

NEW BRUNSWICK, N.J., Feb. 26, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: [JNJ](#)) (the Company) today announced that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) unanimously voted to recommend Emergency Use Authorization (EUA) for the Company's single-shot COVID-19 vaccine candidate for adults 18 and older, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson. The vote was based on a totality of scientific evidence provided by the Company, including efficacy and safety data from the Phase 3 ENSEMBLE trial...

### **Pfizer and BioNTech Initiate a Study as Part of Broad Development Plan to Evaluate COVID-19 Booster and New Vaccine Variants**

February 25, 2021

### **Moderna Announces Additional Capital Investments to Increase Global Manufacturing Capacity for COVID-19 Vaccine**

February 24, 2021

[Moderna Announces it has Shipped Variant-Specific Vaccine Candidate, mRNA-1273.351, to NIH for Clinical Study](#)

February 24, 2021

[Takeda Provides Updates on Phase 1/2 Clinical Trials of Novavax' and Moderna's COVID-19 Vaccine Candidates in Japan](#)

February 23, 2021

.....  
.....

**Emergencies**

**POLIO**

*Public Health Emergency of International Concern (PHEIC)*

**Polio this week as of 24 February 2021**

:: As we head towards International Women's Day (marked on 8 March), GPEI honours two women who left a mark in polio eradication and in women's empowerment within the U.N.

:: On 15 February, polio eradication Gender Champion Arancha González Laya, Minister for Foreign Affairs, European Union and Cooperation of Spain, visited the Notre Dame des Apôtres hospital in N'Djamena, Chad where she administered polio drops to two newborn children. Read more...

""In a special interview, PolioNews (PN) talks to Holger Knaack (HK), President of Rotary International, about why it is more important than ever to support PolioPlus, Rotary's polio eradication program, and what lessons it can offer to the global pandemic response.

***Summary of new WPV and cVDPV viruses this week (AFP cases and ES positives):***

:: **Afghanistan:** six cVDPV2 cases

:: **Pakistan:** one WPV1 and two cVDPV2 cases, six WPV1 and five cVDPV2 positive environmental samples

:: **Congo:** one cVDPV2 case and one cVDPV2 positive environmental sample

:: **Egypt:** one cVDPV2 positive environmental sample

:: **Ethiopia:** one cVDPV2 case

:: **Guinea:** six cVDPV2 cases

:: **Mali:** two cVDPV2 cases

.....  
.....

**WHO/OCHA Emergencies**

***Editor's Note:***

Continuing with this edition, we include information about the last apparent update evident on the WHO emergency country webpages, recognizing almost universal and significant interims since last update regardless of the level of the emergency listed.

**WHO Grade 3 Emergencies** [to 27 Feb 2021]

Democratic Republic of the Congo - *No new digest announcements [Last apparent update: 12 Jan 2021]*

Mozambique floods - *No new digest announcements identified [Last apparent update: 3 November 2020]*

Nigeria - *No new digest announcements identified [Last apparent update: 29 Jun 2020]*

Somalia - *No new digest announcements identified [Last apparent update: 17 July 2020]*

South Sudan - *No new digest announcements identified [Last apparent update: 4 February 2020]*

Syrian Arab Republic - *No new digest announcements identified [Last apparent update: 24 October 2020]*

Yemen - *No new digest announcements identified [Last apparent update: 30 June 2020]*

.....

### **WHO Grade 2 Emergencies** [to 27 Feb 2021]

Afghanistan - *No new digest announcements identified [Last apparent update: 5 July 2020]*

Angola - *No new digest announcements identified [Last apparent update: 03 December 2020]*

Burkina Faso - *No new digest announcements identified [Last apparent update 04 février 2021]*

Burundi - *No new digest announcements identified [Last apparent update: 04 July 2019]*

Cameroon - *No new digest announcements identified [Last apparent update: 22 August 2019]*

Central African Republic - *No new digest announcements identified [Last apparent update: 12 June 2018]*

Ethiopia - *No new digest announcements identified [Last apparent update: 22 August 2019]*

Iran floods 2019 - *No new digest announcements identified [Last apparent update: 2 March 2020]*

Iraq - *No new digest announcements identified [Last apparent update: 21 February 2020]*

Libya - *No new digest announcements identified [Last apparent update: 7 October 2019]*

Malawi Floods - *No new digest announcements identified [Last apparent update: 09 October 2019]*

Measles in Europe - *No new digest announcements identified [Last apparent update: 16-12-2020]*

MERS-CoV - *No new digest announcements identified [Last apparent update: 8 July 2019]*

Mozambique - *No new digest announcements identified [Last apparent update: 03 November 2020]*

Myanmar - *No new digest announcements identified [Last apparent update: :: 3 January 2021]*

Niger - *No new digest announcements identified [Last apparent update: 11 février 2021]*

occupied Palestinian territory - *No new digest announcements identified [Last apparent update: 4 September 2019]*

HIV in Pakistan - *No new digest announcements identified [Last apparent update: 27 August 2019]*

Sao Tome and Principe Necrotizing Cellulitis (2017) - *No new digest announcements*

Sudan - *No new digest announcements identified [Last apparent update: 24 June 2020]*

Ukraine - *No new digest announcements identified [Last apparent update: 1 May 2019]*

Zimbabwe - *No new digest announcements identified [Last apparent update: 10 May 2019]*

.....

### **WHO Grade 1 Emergencies** [to 27 Feb 2021]

Chad - *No new digest announcements identified [Last apparent update: 30 June 2018]*

Djibouti - *No new digest announcements identified [Last apparent update: 25 novembre 2020]*

Kenya - *No new digest announcements identified [Last apparent update: 11 December 2020]*

Mali - *No new digest announcements identified [Last apparent update: 3 May 2017]*

Namibia - viral hepatitis - *No new digest announcements identified [Last apparent update: 20 July 2018]*

Tanzania - *No new digest announcements identified [Last apparent update: 21 October 2020]*

.....  
.....

### **UN OCHA – L3 Emergencies**

*The UN and its humanitarian partners are currently responding to three 'L3' emergencies. This is the global humanitarian system's classification for the response to the most severe, large-scale humanitarian crises.*

#### **Yemen**

:: Yemen: COVID-19 Preparedness and Response Monthly Report (January 2021)

23 February 2021

Syrian Arab Republic - *No new digest announcements identified*

.....

### **UN OCHA – Corporate Emergencies**

*When the USG/ERC declares a Corporate Emergency Response, all OCHA offices, branches and sections provide their full support to response activities both at HQ and in the field.*

#### **East Africa Locust Infestation**

:: Desert Locust situation update 23 February 2021

#### **COVID-19**

:: Global Humanitarian Response Plan COVID-19 Progress Report: Final Progress Report, 22 February 2021

*[See Week in Review above for detail]*

.....  
.....

**WHO & Regional Offices** [to 27 Feb 2021]

25 February 2021

**How WHO transforms funding into action in regions around the world**

25 February 2021

**The life-saving power of medical oxygen**

26 February 2021

Departmental news

**WHO and ITU launch new guide on introduction of dementia risk reduction and carer support programmes using mobile technology**

26 February 2021

Departmental news

**Consultation on discussion paper on Global Action Plan on Epilepsy and Other Neurological Disorders**



25 February 2021  
Joint News Release

**[COVID-19 oxygen emergency impacting more than half a million people in low- and middle-income countries every day, as demand surges](#)**

25 February 2021  
News release

**[El Salvador certified as malaria-free by WHO](#)**

25 February 2021  
Departmental news

**[Four years on, the Global Observatory on Health R&D continues to identify gaps and new trends in the health R&D space](#)**

.....

### **WHO Regional Offices**

*Selected Press Releases, Announcements*

#### **WHO African Region AFRO**

*No new digest content identified*

#### **WHO Region of the Americas PAHO**

*No new digest content identified*

#### **WHO South-East Asia Region SEARO**

*No new digest content identified*

#### **WHO European Region EURO**

:: [WHO/Europe calls for action on post-COVID conditions/"long COVID" 25-02-2021](#)

:: [New WHO expert group to identify gaps and solutions to the mental health impacts of COVID-19 25-02-2021](#)

:: [Spain moves towards a more resilient health coverage policy during COVID-19 25-02-2021](#)

:: [New policy brief calls on decision-makers to support patients as 1 in 10 report symptoms of "long COVID" 25-02-2021](#)

:: [COVID-19 response review in the Republic of Moldova informs next steps 24-02-2021](#)

#### **WHO Eastern Mediterranean Region EMRO**

*No new digest content identified*

#### **WHO Western Pacific Region**

*No new digest content identified*

.....  
.....

**CDC/ACIP [U.S.]** [to 27 Feb 2021]

<http://www.cdc.gov/media/index.html>

<https://www.cdc.gov/vaccines/acip/index.html>

*Latest News Releases, Announcements*

**[Emergency ACIP Meeting - February 28-March 1, 2021](#)**

Virtual meeting. No registration is required.

Meeting times: Feb 28, 11:00am – 4:00pm EST; March 1, 11:00am – 3:00pm EST (times subject to change).

Webcast link: <http://www.ustream.tv/channel/VWBXKBR8af4>

Draft Agenda [includes Janssen COVID-19 vaccine]

**[MMWR News Synopsis Friday, February 26, 2021](#)**

:: [Suspected Recurrent SARS-CoV-2 Infections Among Residents of a Skilled Nursing Facility During a Second COVID-19 Outbreak — Kentucky, July–November 2020](#)

:: [First Identified Cases of SARS-CoV-2 Variant B.1.1.7 in Minnesota — December 2020–January 2021 \(Early Release February 17, 2021\)](#)

:: [Detection of B.1.351 SARS-CoV-2 Variant Strain — Zambia, December 2020 \(Early Release February 17, 2021\)](#)

:: [First Month of COVID-19 Vaccine Safety Monitoring — United States, December 14, 2020–January 13, 2021 \(Early Release February 19, 2021\)](#)

:: [Clusters of SARS-CoV-2 Infection Among Elementary School Educators and Students in One School District — Georgia, December 2020–January 2021 \(Early Release February 22, 2021\)](#)

.....

**[Coronavirus Disease 2019 \(COVID-19\)- CDC](#)**

*Selected Resources*

:: [Overall US COVID-19 Vaccine Distribution and Administration Update as of Fri, 26 Feb 2021 06:00:00 EST Friday, February 26, 2021](#)

:: [First Month of COVID-19 Vaccine Safety Monitoring - United States, December 14, 2020-January 13, 2021 Thursday, February 25, 2021](#)

:: [US COVID-19 Cases Caused by Variants Thursday, February 25, 2021](#)

.....

.....

**Africa CDC** [to 27 Feb 2021]

<http://www.africacdc.org/>

*News*

**[Outbreak Brief 58: Coronavirus Disease 2019 \(COVID-19\) Pandemic](#)**

23 February 2021

.....

.....

**China CDC**

<http://www.chinacdc.cn/en/>

*No new digest content identified.*

**National Health Commission of the People's Republic of China** [to 27 Feb 2021]

<http://en.nhc.gov.cn/>

*News*

**[Feb 27: Daily briefing on novel coronavirus cases in China](#)**

On Feb 26, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland reported 10 new cases of confirmed infections.

**[Children aged 3-17 to be eligible for Sinopharm vaccine](#)**

Chinese drugmaker Sinopharm said people aged 3 to 17 years old who are currently not included in the COVID-19 vaccine rollout will soon become eligible to receive inoculation...

Results from clinical trials involving the younger population have shown "no obvious differences" from trial data concerning those aged 18 to 59 years old, Liu said during an interview with China Central Television on Sunday.

"So we believe those aged 3 to 17 will soon be able to use the vaccines," he said...

**National Medical Products Administration – PRC** [to 27 Feb 2021]

<http://english.nmpa.gov.cn/news.html>

*News*

**[NMPA grants conditional approval to CanSino's recombinant COVID-19 vaccine](#)**

2021-02-27

The National Medical Products Administration (NMPA) conditionally approved the registration application of the recombinant COVID-19 vaccine (adenovirus type-5-vectored vaccine) developed by CanSino Biologics on Feb 25.

**[NMPA conditionally approves COVID-19 vaccine developed by Sinopharm's Wuhan institute](#)**

2021-02-27

The National Medical Products Administration (NMPA) conditionally approved the registration application of the inactivated COVID-19 vaccine (Vero cell) developed by the Wuhan Institute of Biological Products administered by Sinopharm on Feb 25.

.....  
.....

**Organization Announcements**

**Paul G. Allen Frontiers Group** [to 27 Feb 2021]

<https://alleninstitute.org/what-we-do/frontiers-group/news-pr-ess/>

*News*

*No new digest content identified.*

**BARDA – U.S. Department of HHS** [to 27 Feb 2021]

<https://www.phe.gov/about/barda/Pages/default.aspx>

*BARDA News*

*No new digest content identified.*

**BMGF - Gates Foundation** [to 27 Feb 2021]

<http://www.gatesfoundation.org/Media-Center/Press-Releases>

*Press Releases and Statements*

*No new digest content identified.*

**Bill & Melinda Gates Medical Research Institute** [to 27 Feb 2021]

<https://www.gatesmri.org/>

*The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people*

*No new digest content identified.*

**CARB-X** [to 27 Feb 2021]

<https://carb-x.org/>

*News*

02.22.2021 |

**[CARB-X is funding The University of Queensland to develop a new drug targeted to low- and middle-income countries that would breathe new life into existing readily-available antibiotics in the fight against drug-resistance](#)**

CARB-X is awarding up to US\$2.2 million to The University of Queensland's (UQ) Institute for Molecular Bioscience (IMB) to expand its Octapeptin research program to develop a new drug designed for use in low- and middle-income countries (LMICs) where there are high levels of drug-resistant bacteria.

**Center for Vaccine Ethics and Policy – GE2P2 Global Foundation** [to 27 Feb 2021]

<https://centerforvaccineethicsandpolicy.net/>

*News/Analysis/Statements*

Past weekly editions of *Vaccines and Global Health: The Week in Review* are [available here](#).

**CEPI – Coalition for Epidemic Preparedness Innovations** [to 27 Feb 2021]

<http://cepi.net/>

*Latest News*

**[In the fight against novel COVID-19 variants, Norway and Germany provide vital additional funds to CEPI](#)**

*The donations come at a critical time as CEPI works to advance vaccines against COVID-19 variants.*  
25 Feb 2021

Norway, one of the co-founders of CEPI, [announced this week](#) that it will contribute US \$24 million (NOK 200 million) towards CEPI's R&D efforts to future-proof vaccines against current and future variants of the SARS-CoV-2 virus.

The financial commitment follows the [US \\$145 million \(EUR 120 million\) donation announced by the Government of Germany](#) last week following the extraordinary G7 virtual summit to support CEPI's COVID-19 vaccine programmes. The funding is as part of a wider US \$1.82 billion (EUR 1.5 billion) donation package to partners of the Access to COVID-19 Tools (ACT) Accelerator.

These investments come at a critical time of the COVID-19 pandemic, with CEPI seeking to expand its efforts and respond to the rapidly evolving crisis...

### **[COVID-19 vaccine doses shipped by the COVAX Facility head to Ghana, marking beginning of global rollout](#)**

600,000 doses of the AstraZeneca/Oxford vaccine licensed to Serum Institute of India have arrived in Accra, Ghana; further deliveries are expected this week.  
24 Feb 2021

### **DARPA – Defense Advanced Research Projects Agency** [to 27 Feb 2021]

<https://www.darpa.mil/>

*News*

*No new digest content identified.*

### **Duke Global Health Innovation Center** [to 27 Feb 2021]

<https://dukeghic.org/>

*Launch and Scale Speedometer*

*No new digest content identified.*

### **EDCTP** [to 27 Feb 2021]

<http://www.edctp.org/>

*The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials*

25 February 2021

### **[GHIT and EDCTP co-invest additional €7.8 million in access programme for treatment of schistosomiasis in preschool-aged children](#)**

### **Emory Vaccine Center** [to 27 Feb 2021]

<http://www.vaccines.emory.edu/>

*Vaccine Center News*

*No new digest content identified.*

### **European Commission** [to 27 Feb 2021]

<http://europa.eu/rapid/search-result.htm?query=18&locale=en&page=1>

*Latest*

*News* 26 February 2021

### **[Von der Leyen at the video conference of the members of the European Council discusses vaccination, security and defence, and Southern Neighbourhood](#)**

To continue increasing the speed of our vaccination effort, she called on everyone to play a role. The Commission is working with the companies to ramp up production and address bottlenecks in the supply, she explained.

News 23 February 2021

**[President von der Leyen joins the Global Citizen campaign to end COVID-19 and kick start a global recovery](#)**

"We have to fight the pandemic right now, but we also have to address its broader impact on the most vulnerable and tackle the root causes," said Ursula von der Leyen, President of the European Commission.

**European Medicines Agency** [to 27 Feb 2021]

<http://www.ema.europa.eu/ema/>

*News & Press Releases*

**[News: Meeting highlights from the Committee for Medicinal Products for Human Use \(CHMP\) 22-25 February 2021](#)**

CHMP, Last updated: 26/02/2021

**[News: Adapting COVID-19 vaccines to SARS-CoV-2 variants: guidance for vaccine manufacturers](#)**

CHMP, Last updated: 25/02/2021

EMA has issued guidance outlining the requirements for manufacturers planning to modify their COVID-19 vaccines in order to address coronavirus (SARS-CoV-2) variants.

Currently, three vaccines are authorised for use in the EU: Comirnaty, COVID-19 Vaccine Moderna and COVID-19 Vaccine AstraZeneca. Viruses typically mutate and several variant strains of SARS-CoV-2 have already been identified worldwide. The three authorised vaccines provide protection against the variants that are currently prevalent across Europe. However, it appears that with continued mutations and new variants emerging, authorised vaccines may need to be adapted, in time to ensure continued protection. Initial data indicates that some of these variants may have an impact on the level of protection provided by COVID-19 vaccines against infection and disease.

Therefore, it is an urgent public health priority to define an expedited regulatory process for the adaptation of vaccines to protect against current or future variants. There are ongoing discussions at international level on how to approach variants and vaccines in a coordinated way.

EMA's human medicines committee (CHMP) has adopted a reflection paper which details the laboratory (non-clinical), clinical, quality and manufacturing data needed to support the approval of such 'variant' vaccines.

The assumption behind the CHMP's guidance is that a new variant vaccine would largely rely on the same technology and platform as the 'parent' vaccine - a vaccine already approved in the EU for the prevention of COVID-19. The difference would be in the specific structure (antigen) selected to trigger the immune response in the body...

**[Reflection paper on the regulatory requirements for vaccines intended to provide protection against variant strain\(s\) of SARS-CoV-2 \(PDF/240.55 KB\) \(new\)](#)**

**[News: International cooperation to align approaches for regulation of COVID-19 vaccines and medicines](#)**

Last updated: 25/02/2021

Regulators around the globe are committed to aligning their regulatory requirements and addressing knowledge gaps to facilitate the development, authorisation and monitoring of safe, effective and high-quality vaccines and medicines against COVID-19. This was highlighted in a series of regulatory workshops, convened under the umbrella of the [International Coalition of Medicines Regulatory Authorities \(ICMRA\)](#) in the first weeks of 2021, which focused on three areas: responding to emerging COVID-19 virus variants, addressing knowledge gaps regarding COVID-19 vaccines and treatments in pregnant and breastfeeding women, and strengthening collaboration on safety monitoring of vaccines...

### [News: EMA starts rolling review of Celltrion antibody regdanvimab for COVID-19](#)

Last updated: 24/02/2021

#### **European Vaccine Initiative** [to 27 Feb 2021]

<http://www.euvaccine.eu/>

*Latest News*

*No new digest content identified.*

#### **FDA** [to 27 Feb 2021]

<https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/default.htm>

*Press Announcements / Selected Details*

#### [February 26, 2021 - FDA Statement on Vaccines and Related Biological Products Advisory Committee Meeting](#)

Following today's positive advisory committee meeting outcome regarding the Janssen Biotech Inc. COVID-19 Vaccine, the U.S. Food and Drug Administration has informed the sponsor that it will rapidly work toward finalization and issuance of an emergency use authorization. The agency has also notified our federal partners involved in vaccine allocation and distribution so they can execute their plans for timely vaccine distribution...

#### [February 26, 2021 - Coronavirus \(COVID-19\) Update: February 26, 2021](#)

#### [February 25, 2021 - Coronavirus \(COVID-19\) Update: FDA Allows More Flexible Storage, Transportation Conditions for Pfizer-BioNTech COVID-19 Vaccine](#)

#### **FDA - COVID-19 Vaccines** [to 27 Feb 2021]

[www.fda.gov/covid19vaccines](http://www.fda.gov/covid19vaccines)

*News and Updates; Upcoming Events*

#### [FDA Statement on Vaccines and Related Biological Products Advisory Committee Meeting](#)

02/26/2021

Following today's positive advisory committee meeting outcome regarding the Janssen Biotech Inc. COVID-19 Vaccine, the FDA has informed the sponsor that it will rapidly work toward finalization and issuance of an emergency use authorization.

#### **Fondation Merieux** [to 27 Feb 2021]

<http://www.fondation-merieux.org/>

*News, Events*



*Mérieux Foundation co-organized event*

**[MERACON: Returning to rabies elimination in 2021 webinar](#)**

February 26, 2021 - 9:00am -12:00pm (CET)

*Context*

The COVID-19 pandemic has hampered global travel and has placed a strain on public health systems globally. Because of this, many rabies activities were postponed or cancelled in 2020. Similarly, the planned in-person regional MERACON workshop that was initially scheduled for mid-2020 was postponed to 2021. As a means to continue remote support, foster collaboration and continue to drive progress towards rabies elimination in the MERACON countries, the MERACON steering committee has scheduled a digital meeting in webinar format. This webinar will act as a precursor to a more detailed workshop later in the year which we hope to host in-person (COVID-19 restrictions permitting).

**Gavi** [to 27 Feb 2021]

<https://www.gavi.org/>

*News Releases*

**[COVID-19 vaccine doses shipped by the COVAX Facility head to Ghana, marking beginning of global roll-out](#)**

**[No-fault compensation programme for COVID-19 vaccines is a world first](#)**

*[See COVID above for detail on these announcements]*

**GHIT Fund** [to 27 Feb 2021]

<https://www.ghitfund.org/newsroom/press>

*GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that*

*Press Releases*

February 25, 2021

**[GHIT and EDCTP co-invest additional 7.8 million Euro in the Pediatric Praziquantel Consortium's access program to ensure treatment of schistosomiasis for preschool-aged children](#)**

**Global Fund** [to 27 Feb 2021]

<https://www.theglobalfund.org/en/news/>

*News & Stories*

News

**[The Republic of the Congo and Global Fund Sign New Grants to Increase Access to HIV, TB and Malaria Prevention and Treatment](#)**

25 February 2021

The Global Fund, the Government of the Republic of the Congo and health partners launched the implementation of two new grants to strengthen prevention and treatment services to fight HIV, TB and malaria and build resilient and sustainable systems for health.

*News*

**[Burkina Faso and Global Fund Launch New Grants to Accelerate Progress against HIV, TB and Malaria](#)**

25 February 2021

The Government of Burkina Faso, the Global Fund and health partners strengthened their partnership by launching four new grants to accelerate the end of AIDS, tuberculosis and malaria as epidemics and strengthen health systems. The new grants will cover the 2021-2023 implementation period.

**Global Research Collaboration for Infectious Disease Preparedness [GloPID-R]** [to 27 Feb 2021]

<https://www.glopid-r.org/news/>

*News*

*No new digest content identified.*

**Hilleman Laboratories** [to 27 Feb 2021]

<http://www.hillemanlabs.org/>

*No new digest content identified.*

**Human Vaccines Project** [to 27 Feb 2021]

<http://www.humanvaccinesproject.org/media/press-releases/>

*Press Releases*

*No new digest content identified.*

**IAVI** [to 27 Feb 2021]

<https://www.iavi.org/newsroom>

*PRESS RELEASES/FEATURES*

*No new digest content identified.*

**International Coalition of Medicines Regulatory Authorities [ICMRA]**

<http://www.icmra.info/drupal/en/news>

*Selected Statements, Press Releases, Research*

*No new digest content identified.*

**International Generic and Biosimilar Medicines Association [IGBA]**

<https://www.igbamedicines.org/>

*\*News*

*Press Releases/Announcements*

*No new digest content identified.*

**IFFIm**

<http://www.iffim.org/>

*Press Releases/Announcements*

*No new digest content identified.*

**IFRC** [to 27 Feb 2021]

<http://media.ifrc.org/ifrc/news/press-releases/>

*Selected Press Releases, Announcements*

*No new digest content identified.*

**Institut Pasteur** [to 27 Feb 2021]

<https://www.pasteur.fr/en/press-area>

*Press release 26.02.2021*

**[Covid-19: Keeping schools as safe as possible](#)**

A year into the pandemic, and confronted with continued resurgence in transmission, over 800 million schoolchildren, more than half the world's student population, still face substantial disruptions to their education...

[Read the full editorial in the \*BMJ\*](#)

**IRC International Rescue Committee** [to 27 Feb 2021]

<http://www.rescue.org/press-release-index>

*Media highlights [Selected]*

*No new digest content identified.*

**IVAC** [to 27 Feb 2021]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

*Updates; Events*

*No new digest content identified.*

**IVI** [to 27 Feb 2021]

<http://www.ivi.int/>

*Selected IVI News, Announcements, Events*

**[George Bickerstaff re-elected Chairperson of the International Vaccine Institute's Board of Trustees](#)**

February 22, 2021, SEOUL, Korea – The International Vaccine Institute (IVI) announced today that its Board of Trustees (BOT) re-elected Mr. George Bickerstaff as Chairperson of the BOT. His second three-year term will begin this May...

**JEE Alliance** [to 27 Feb 2021]

<https://www.jeealliance.org/>

*Selected News and Events*

*No new digest content identified.*

**Johns Hopkins Center for Health Security** [to 27 Feb 2021]

<https://www.centerforhealthsecurity.org/news/center-news/>

*Center News*

**[New Report: Crisis Standards of Care: Lessons from New York City Hospitals' COVID-19 Experience: The Emergency Medicine Perspective](#)**

February 25, 2021

**MSF/Médecins Sans Frontières** [to 27 Feb 2021]

<http://www.msf.org/>

*Latest [Selected Announcements]*

*DRC Ebola outbreaks*

**[MSF responds in North Kivu to twelfth Ebola outbreak in DRC](#)**

Project Update 25 Feb 2021

**National Vaccine Program Office - U.S. HHS** [to 27 Feb 2021]

<https://www.hhs.gov/vaccines/about/index.html>

*Upcoming Meetings/Latest Updates*

*No new digest content identified.*

**NIH** [to 27 Feb 2021]

<http://www.nih.gov/news-events/news-releases>

*News Releases*

**[NIH study finds that people with SARS-CoV-2 antibodies may have a low risk of future infection](#)**

February 24, 2021 — Results may explain why reinfection appears to be relatively rare.

**[Monoclonal antibodies against MERS coronavirus show promise in Phase 1 NIH-sponsored trial](#)**

February 23, 2021 — Antibodies were well tolerated and generally safe when administered simultaneously to healthy adults.

**UN OCHA** [to 27 Feb 2021]

<https://www.unocha.org/>

*Research*

**[Global Humanitarian Response Plan COVID-19 Progress Report: Final Progress Report](#)**

OCHA 22 Feb 2021

PDF: [https://reliefweb.int/sites/reliefweb.int/files/resources/GHRP\\_ProgressReport\\_22FEB.pdf](https://reliefweb.int/sites/reliefweb.int/files/resources/GHRP_ProgressReport_22FEB.pdf)

*COVID-19 AND THE HUMANITARIAN LANDSCAPE*

2020 was a year like no other. Amidst on-going humanitarian crises, largely fuelled by conflict and violence but also driven by the effects of climate change – such as the largest locust infestation in a generation – the world had to contend with a global pandemic. In less than one year (March-December 2020), more than 82 million COVID-19 cases and 1.8 million deaths were recorded. In that timeframe, out of the global COVID-19 totals, 30 per cent of COVID-19 cases and 39 per cent deaths were recorded in GHRP countries...

**PATH** [to 27 Feb 2021]

[https://www.path.org/media-center/  
Press Releases](https://www.path.org/media-center/Press-Releases)  
*No new digest content identified.*

**Sabin Vaccine Institute** [to 27 Feb 2021]  
<http://www.sabin.org/updates/pressreleases>  
*Statements and Press Releases*  
*No new digest content identified.*

**UNAIDS** [to 27 Feb 2021]  
<http://www.unaids.org/en>  
*Selected Press Releases/Reports/Statements*  
25 February 2021

**[COVID-19 spurs on multimonth dispensing of HIV treatment in Cambodia](#)**

**UNHCR** Office of the United Nations High Commissioner for Refugees [to 27 Feb 2021]  
<http://www.unhcr.org/en-us/media-centre.html>  
*Selected Announcements*  
*No new digest content identified.*

**UNICEF** [to 27 Feb 2021]  
<https://www.unicef.org/media/press-releases>  
*Selected Press releases, Statements*  
*Press release*  
02/26/2021

**[Latter-day Saint Charities commits US\\$20 million in support of UNICEF's global COVID-19 response](#)**

Latter-day Saint Charities becomes the single largest private sector donor to date to support UNICEF's ACT-Accelerator and COVAX work

*Press release*  
02/26/2021

**[Côte d'Ivoire becomes second African country and first French-speaking country to receive vaccine doses via COVAX Facility](#)**

*News note*  
02/25/2021

**[UNICEF signs COVID-19 vaccine supply agreement with AstraZeneca](#)**

*Press release*  
02/24/2021

**[COVID-19 vaccine doses shipped by the COVAX Facility head to Ghana, marking beginning of global rollout](#)**

*Statement*

02/24/2021

**[Ghana becomes recipient of historic first shipment of COVAX vaccine](#)**

Statement by UNICEF Representative in Ghana, Anne-Claire Dufay and WHO Representative to Ghana, Dr Francis Kasolo on the arrival of the first COVID-19 vaccines in Accra

**Unitaid** [to 27 Feb 2021]

<https://unitaid.org/>

*Featured News*

25 February 2021

**[COVID-19 oxygen emergency impacting more than half a million people in low- and middle-income countries every day, as demand surges](#)**

:: More than half a million COVID-19 patients in LMICs estimated to need oxygen treatment every day.

:: New assessments show US\$90 million immediate funding required to meet urgent need in up to 20 low- and middle-income countries (LMICs). Unitaid and Wellcome will make an immediate contribution of up to US\$20 million in total for the emergency response.

:: COVID-19 Oxygen Emergency Taskforce brings together key organisations working on oxygen access under ACT-Accelerator Therapeutics pillar, as COVID-19 surges and preventable deaths occur

:: Taskforce partners will work together to measure oxygen demand, work with financing partners, and secure oxygen supplies and technical support for worst-affected countries

**Vaccination Acceptance Research Network (VARN)** [to 27 Feb 2021]

<https://vaccineacceptance.org/news.html#header1-2r>

*Announcements*

*No new digest content identified.*

**Vaccine Confidence Project** [to 27 Feb 2021]

<http://www.vaccineconfidence.org/>

*News, Research and Reports*

*No new digest content identified.*

**Vaccine Education Center – Children’s Hospital of Philadelphia** [to 27 Feb 2021]

<http://www.chop.edu/centers-programs/vaccine-education-center>

*News*

**[Vaccine Update for Providers = February 2021](#)**

**Wellcome Trust** [to 27 Feb 2021]

<https://wellcome.ac.uk/news>

*Opinion*

**[COVAX campaign for equitable vaccine access delivers first doses to West Africa](#)**

The largest mass vaccination campaign in history has begun. Ghana and Cote D’Ivoire have become the first countries to receive Covid-19 vaccines through COVAX. Richard Hatchett, CEO at the Coalition

for Epidemic Preparedness Innovations (CEPI), the vaccine research and development partnership co-leading COVAX, reacts to this historic moment.  
25 February 2021

**The Wistar Institute** [to 27 Feb 2021]  
<https://www.wistar.org/news/press-releases>  
*Press Releases*  
*No new digest content identified.*

**WFPHA: World Federation of Public Health Associations** [to 27 Feb 2021]  
<https://www.wfpha.org/>  
*Latest News*  
**[Operation Vaccination: An Analysis of Global COVID-19 Vaccine Rollout Strategies](#)** is a weekly post which will explore the policy, logistics, obstacles and controversies involved in procuring and distributing vaccines against COVID-19.  
The theme of this week is "Communication and Trust: Keeping the Public Informed and On Board". Focusing on the 9 countries featured in this blog (Brazil, India, Indonesia, Ireland, Israel, Nigeria, Taiwan, UK, US) and COVAX, communication strategies are analysed, focusing on mitigating vaccine hesitancy and explanations of the structure and timing of immunization drives..

**World Bank** [to 27 Feb 2021]  
<http://www.worldbank.org/en/news/all>  
*Selected News, Announcements*  
**[IDA's COVID-19 Response: Speed, Scale and Selectivity](#)**  
Since the beginning of the COVID-19 pandemic, IDA has provided substantial support to IDA countries' crisis response and development programs, helping them transition to a resilient and...  
Date: February 23, 2021 Type: *Infographic [full image at title link]*  
*[The International Development Association (IDA) is the part of the World Bank that helps the world's poorest countries. Overseen by 173 shareholder nations, IDA aims to reduce poverty by providing zero to low-interest loans (called "credits") and grants for programs that boost economic growth, reduce inequalities, and improve people's living conditions.]*

**World Organisation for Animal Health (OIE)** [to 27 Feb 2021]  
<https://www.oie.int/en/for-the-media/press-releases/2021/>  
*Press Releases*  
*No new digest content identified.*

.....

**ARM [Alliance for Regenerative Medicine]** [to 27 Feb 2021]  
[Press Releases - Alliance for Regenerative Medicine \(alliancerm.org\)](https://www.alliancerm.org/)  
*Press Releases*  
*No new digest content identified.*



**BIO** [to 27 Feb 2021]

<https://www.bio.org/press-releases>

*Press Releases*

*No new digest content identified.*

**DCVMN – Developing Country Vaccine Manufacturers Network** [to 27 Feb 2021]

<http://www.dcvmn.org/>

*News; Upcoming events*

*No new digest content identified.*

**ICBA – International Council of Biotechnology Associations** [to 27 Feb 2021]

<https://internationalbiotech.org/news/>

*News*

*No new digest content identified.*

**IFPMA** [to 27 Feb 2021]

<http://www.ifpma.org/resources/news-releases/>

*Selected Press Releases, Statements, Publications*

*No new digest content identified.*

**PhRMA** [to 27 Feb 2021]

<http://www.phrma.org/>

*Selected Press Releases, Statements*

**[Coming together to fight COVID-19: A conversation with Paul Perreault, CEO and Managing Director of CSL](#)**

February 24, 2021

This year, our industry has been working around the clock to combat the COVID-19 virus, including developing effective therapeutics to treat COVID-19 and vaccines to prevent future infections. I had the opportunity to connect with Paul Perreault, CEO and Managing Director of CSL Limited, the world's third largest biotech, about the company's efforts to address COVID-19.

*Blog Post*

**[ICYMI: Report provides actionable recommendations to strengthen America's preparedness and future health crises response](#)**

February 22, 2021

As America's biopharmaceutical researchers continue working around the clock to fight COVID-19, leaders in the health care ecosystem have come together to provide recommendations to strengthen America's preparedness and future health care crises response...

The report provides a comprehensive set of recommendations to improve the nation's capabilities for disaster preparedness and response. The recommendations include:

:: Creation by the White House of a standing disaster preparedness group that will include private sector expertise in areas such as production capacity, supply chain and distribution, and acute care delivery.

:: Modernizing the health care supply chain through digitalization, automation, and predictive analytics, with standardized approaches for allocating resources based on need and equity to prevent bidding wars between states and healthcare providers.

:: Improving supply chain resilience with strategic incentives such as zero percent loans, federally-guaranteed purchase commitments, and geographic diversification of production for critical medical products.

:: Construction of a 21st century public health early warning system that will utilize all available electronic health records and public health data collection.

:: Legislation and regulatory reform to create rapid response capabilities in areas such as medical licensure portability, telehealth accessibility, and swift access to PPE stockpiles.

:: Creation of measures to ensure health equity and address disparities, identifying high-risk vulnerable populations and directing resources accordingly.

*Blog Post*

\* \* \* \*

### **Journal Watch**

*Vaccines and Global Health: The Week in Review* continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)

### **AJOB Empirical Bioethics**

Volume 12, 2020 Issue 1

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]

### **AMA Journal of Ethics**

Volume 23, Number 2: E83-211 Feb 2021

<https://journalofethics.ama-assn.org/issue/racial-and-ethnic-health-equity-us-part-1>

#### ***Racial and Ethnic Health Equity in the US: Part 1***

Health equity is defined by the World Health Organization as the “absence of unfair and avoidable or remediable differences in health among social groups.” Domestically and globally, health inequity is not a historical accident. Inequity today is not *unfortunate*—that is, not a product of a mere turn of the proverbial cosmic wheel—but *unjust*—that is, generated by colonial, White supremacist policies and practices structured and maintained over time, forged to persist in hierarchies that serve some of us, our ancestors, and our descendants well and some of us, our ancestors, and our descendants ill. This first of a 2-part theme issue focuses specifically on racial and ethnic inequity in morbidity, mortality, and access to services that are endemic to American life. We investigate health inequity as a product of transgenerational patterns of oppression that must be remediated by all of us compassionately and more deliberately and quickly than they were created.

**American Journal of Infection Control**

March 2021 Volume 49 Issue 3 p281-408

<http://www.ajicjournal.org/current>

[New issue; No digest content identified]

**American Journal of Preventive Medicine**

March 2021 Volume 60 Issue 3 p311-452

<http://www.ajpmonline.org/current>

*Research Articles*

**[Asynchrony Between Individual and Government Actions Accounts for Disproportionate Impact of COVID-19 on Vulnerable Communities](#)**

Moustafa Abdalla, Arjan Abar, Evan R. Beiter, Mohamed Saad

Published online: November 13, 2020

**[Effect of Medicaid Expansions on HIV Diagnoses and Pre-Exposure Prophylaxis Use](#)**

Bitu Fayaz Farkhad, David R. Holtgrave, Dolores Albarracín

Published online: January 24, 2021

**[Potential Clinical and Economic Value of Norovirus Vaccination in the Community Setting](#)**

Sarah M. Bartsch, Kelly J. O'Shea, Patrick T. Wedlock, Marie C. Ferguson, Sheryl S. Siegmund, Bruce Y. Lee

Published online: January 26, 2021

**[Geographic Variation in Human Papillomavirus Vaccination Initiation and Completion Among Young Adults in the U.S.](#)**

Eric Adjei Boakye, Oluwole A. Babatunde, Maggie Wang,...Wiley Jenkins, Minjee Lee, Minjin Kim

Published online: December 17, 2020

**American Journal of Public Health**

March 2021 111(3)

<http://ajph.aphapublications.org/toc/ajph/current>

*EDITORIALS*

**[Preparing the Public Health Workforce for the Post-COVID-19 Era](#)**

Health Education, Public Health Practice, Public Health Workers

Sandro Galea and Roger Vaughan

*PERSPECTIVES*

**[The Syndemics of Emergency: How COVID-19 Demands a Holistic View of Public Health Promotion and Preparedness](#)**

Public Health Practice, Health Promotion, Injury/Emergency Care/Violence

Vinyas Harish

**[Communicating Effectively About Emergency Use Authorization and Vaccines in the COVID-19 Pandemic](#)**

Government, Media, Immunization/Vaccines, Prevention, Health Promotion  
Sandra Crouse Quinn, Amelia M. Jamison and Vicki Freimuth

**[Building Trust in COVID-19 Vaccines and Beyond Through Authentic Community Investment](#)**

Other Race/Ethnicity, Immunization/Vaccines, Prevention, Community Health, Race/Ethnicity  
Bisola O. Ojikutu, Kathryn E. Stephenson, Kenneth H. Mayer and Karen M. Emmons

**[Enhancing the WHO's Proposed Framework for Distributing COVID-19 Vaccines Among Countries](#)**

Global Health, Ethics  
Ezekiel J. Emanuel, Florencia Luna, G. Owen Schaefer, Kok-Chor Tan and Jonathan Wolff

*INTERNATIONAL FORUM*

**[Equitable Enforcement of Pandemic-Related Public Health Laws: Strategies for Achieving Racial and Health Justice](#)**

Government, Socioeconomic Factors, Health Law, Health Policy  
Maya Hazarika Watts, Katie Hannon Michel, Jessica Breslin and Elizabeth Tobin-Tyler

**American Journal of Tropical Medicine and Hygiene**

Volume 104, Issue 1, January 2021

<http://www.ajtmh.org/content/journals/14761645/104/1>

[Reviewed earlier]

**Annals of Internal Medicine**

February 2021 Volume 174, Issue 2

<http://annals.org/aim/issue>

[Reviewed earlier]

**Artificial Intelligence – An International Journal**

Volume 292 March 2021

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/292/suppl/C>

[Reviewed earlier]

**BMC Cost Effectiveness and Resource Allocation**

<http://resource-allocation.biomedcentral.com/>

(Accessed 27 Feb 2021)

[No new digest content identified]

**BMJ Global Health**

February 2021 - Volume 6 - 2

<https://gh.bmj.com/content/6/2>

[Reviewed earlier]

## **BMC Health Services Research**

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 27 Feb 2021)

[No new digest content identified]

## **BMC Infectious Diseases**

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 27 Feb 2021)

[No new digest content identified]

## **BMC Medical Ethics**

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 27 Feb 2021)

*Research article*

### **[Digital tools in the informed consent process: a systematic review](#)**

Providing understandable information to patients is necessary to achieve the aims of the Informed Consent process: respecting and promoting patients' autonomy and protecting patients from harm. In recent decades, new, primarily digital technologies have been used to apply and test innovative formats of Informed Consent. We conducted a systematic review to explore the impact of using digital tools for Informed Consent in both clinical research and in clinical practice. Understanding, satisfaction and participation were compared for digital tools versus the non-digital Informed Consent process...

Digital technologies for informed consent were not found to negatively affect any of the outcomes, and overall, multimedia tools seem desirable. Multimedia tools indicated a higher impact than videos only. Presence of a researcher may potentially enhance efficacy of different outcomes in research IC processes. Studies were heterogeneous in design, making evaluation of impact challenging. Robust study design including standardization is needed to conclusively assess impact.

Authors: Francesco Gesualdo, Margherita Daverio, Laura Palazzani, Dimitris Dimitriou, Javier Diez-Domingo, Jaime Fons-Martinez, Sally Jackson, Pascal Vignally, Caterina Rizzo and Alberto Eugenio Tozzi  
27 February 2021

## **BMC Medicine**

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 27 Feb 2021)

### **[The epidemiologic impact and cost-effectiveness of new tuberculosis vaccines on multidrug-resistant tuberculosis in India and China](#)**

*Despite recent advances through the development pipeline, how novel tuberculosis (TB) vaccines might affect rifampicin-resistant and multidrug-resistant tuberculosis (RR/MDR-TB) is unknown. We investigated the...*

Authors: Chathika K Weerasuriya, Rebecca C Harris, C Finn McQuaid, Fiammetta Bozzani, Yunzhou Ruan, Renzhong Li, Tao Li, Kirankumar Rade, Raghuram Rao, Ann M Ginsberg, Gabriela B Gomez and Richard G White

Citation: BMC Medicine 2021 19:60

Content type: Research article

Published on: 26 February 2021

### **Following the science? Comparison of methodological and reporting quality of covid-19 and other research from the first wave of the pandemic**

*Following the initial identification of the 2019 coronavirus disease (covid-19), the subsequent months saw substantial increases in published biomedical research. Concerns have been raised in both scientific and lay press around the quality of some of this research. We assessed clinical research from major clinical journals, comparing methodological and reporting quality of covid-19 papers published in the first wave (here defined as December 2019 to May 2020 inclusive) of the viral pandemic with non-covid papers published at the same time... Across various measures, we have demonstrated that covid-19 research from the first wave of the pandemic was potentially of lower quality than contemporaneous non-covid research. While some differences may be an inevitable consequence of conducting research during a viral pandemic, poor reporting should not be accepted.*

Authors: Terence J. Quinn, Jennifer K. Burton, Ben Carter, Nicola Cooper, Kerry Dwan, Ryan Field, Suzanne C. Freeman, Claudia Geue, Ping-Hsuan Hsieh, Kris McGill, Clareece R. Nevill, Dikshyanta Rana, Alex Sutton, Martin Taylor Rowan and Yiqiao Xin

Citation: BMC Medicine 2021 19:46

Content type: Research article

Published on: 23 February 2021

### **BMC Pregnancy and Childbirth**

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 27 Feb 2021)

[No new digest content identified]

### **BMC Public Health**

<http://bmcpublihealth.biomedcentral.com/articles>

(Accessed 27 Feb 2021)

[No new digest content identified]

### **BMC Research Notes**

<http://www.biomedcentral.com/bmcrenotes/content>

(Accessed 27 Feb 2021)

[No new digest content identified]

### **BMJ Open**

February 2021 - Volume 11 - 2

<https://bmjopen.bmj.com/content/11/2>

[Reviewed earlier]

### **Bulletin of the World Health Organization**

Volume 99, Number 2, February 2021, 77-168

<https://www.who.int/bulletin/volumes/99/2/en/>

[Reviewed earlier]

### **Child Care, Health and Development**

Volume 47, Issue 2 Pages: 143-296 March 2021

<https://onlinelibrary.wiley.com/toc/13652214/current>

[Reviewed earlier]

### **Clinical Pharmacology & Therapeutics**

Volume 109, Issue 2 Pages: 271-546 February 2021

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

[Reviewed earlier]

### **Clinical Therapeutics**

January 2021 Volume 43 Issue 1 p1-210, e1-e32

<http://www.clinicaltherapeutics.com/current>

*Review*

#### **[Regulatory Agilities in the Time of COVID-19: Overview, Trends, and Opportunities](#)**

*While many regulatory measures have been introduced temporarily as a response to the COVID-19 crisis, there are opportunities for leveraging an understanding from these approaches in order to collectively achieve more efficient regulatory systems and to mitigate and address the impact of COVID-19 and further future-proof the regulatory environment.*

Winona Rei Bolisliis, et al

Published online: November 30, 2020

*Original Research*

#### **[Reduced Mortality After Oral Polio Vaccination and Increased Mortality After Diphtheria-tetanus-pertussis Vaccination in Children in a Low-income Setting](#)**

Christian Bjerregård Øland, et al

Published online: December 02, 2020

### **Clinical Trials**

Volume 18 Issue 1, February 2021

<https://journals.sagepub.com/toc/ctja/18/1>

[Reviewed earlier]

### **Conflict and Health**

<http://www.conflictandhealth.com/>

[Accessed 27 Feb 2021]

[No new digest content identified]

### **Contemporary Clinical Trials**

Volume 100 January 2021



<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/100/suppl/C>  
[Reviewed earlier]

### **The CRISPR Journal**

Volume 4, Issue 1 / February 2021

<https://www.liebertpub.com/toc/crispr/4/1>

*Correspondence Free*

#### **[Re: Human Germline and Heritable Genome Editing: The Global Policy Landscape](#)**

Guillaume Levrier

Pages:3–4

Published Online:19 February 2021

<https://doi.org/10.1089/crispr.2021.29121.gle>

#### **[Response to Levrier re: Human Germline and Heritable Genome Editing: The Global Policy Landscape](#)**

Marcy Darnovsky, Katie Hasson, and Timothy M. Krahn

Pages:4–5

Published Online:19 February 2021

*Perspectives Open Access*

#### **[A Code of Ethics for Gene Drive Research](#)**

George J. Annas, et al

Pages:19–24

Published Online:10 February 2021

<https://doi.org/10.1089/crispr.2020.0096>

*Abstract*

Gene drives hold promise for use in controlling insect vectors of diseases, agricultural pests, and for conservation of ecosystems against invasive species. At the same time, this technology comes with potential risks that include unknown downstream effects on entire ecosystems as well as the accidental or nefarious spread of organisms that carry the gene drive machinery. A code of ethics can be a useful tool for all parties involved in the development and regulation of gene drives and can be used to help ensure that a balanced analysis of risks, benefits, and values is taken into consideration in the interest of society and humanity. We have developed a code of ethics for gene drive research with the hope that this code will encourage the development of an international framework that includes ethical guidance of gene drive research and is incorporated into scientific practice by gaining broad agreement and adherence.

### **Current Genetic Medicine Reports**

Volume 8, issue 4, December 2020

<https://link.springer.com/journal/40142/volumes-and-issues/8-4>

[Reviewed earlier]

### **Current Opinion in Infectious Diseases**

February 2021 - Volume 34 - Issue 1

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

[Reviewed earlier]

**Current Protocols in Human Genetics**

Volume 108, Issue 1 December 2020

<https://currentprotocols.onlinelibrary.wiley.com/toc/19348258/current>

[Reviewed earlier]

**Developing World Bioethics**

Volume 20, Issue 4 Pages: 173-230 December 2020

<https://onlinelibrary.wiley.com/toc/14718847/current>

[Reviewed earlier]

**Development in Practice**

Volume 30, Issue 8, 2020

<http://www.tandfonline.com/toc/cdip20/current>

[Reviewed earlier]

**Disaster Medicine and Public Health Preparedness**

Volume 14 - Issue 5 - October 2020

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[Reviewed earlier]

**Disasters**

Volume 45, Issue 1 Pages: 1-252 January 2021

<https://onlinelibrary.wiley.com/toc/14677717/current>

[Reviewed earlier]

**EMBO Reports**

Volume 22 Issue 2 3 February 2021

<https://www.embopress.org/toc/14693178/current>

[Reviewed earlier]

**Emerging Infectious Diseases**

Volume 27, Number 3—March 2021

<http://wwwnc.cdc.gov/eid/>

Expedited Articles

[\*\*Genomic Evidence of SARS-CoV-2 Reinfection Involving E484K Spike Mutation, Brazil\*\*](#)

*Perspective*

**[Parallels and Mutual Lessons in Tuberculosis and COVID-19 Transmission, Prevention, and Control \[PDF - 607 KB - 6 pages\]](#)**

P. C. Hopewell et al.

**Epidemics**

Volume 33 December 2020

<https://www.sciencedirect.com/journal/epidemics/vol/33/suppl/C>

[Reviewed earlier]

**Epidemiology and Infection**

Volume 149 - 2021

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

**Ethics & Human Research**

Volume 43, Issue 1 January–February 2021

<https://onlinelibrary.wiley.com/toc/25782363/current>

***When disadvantaged by research • Privacy and medical records • Research misconduct***

[Reviewed earlier]

**The European Journal of Public Health**

Volume 31, Issue 1, February 2021

<https://academic.oup.com/eurpub/issue/31/1>

[Reviewed earlier]

**Expert Review of Vaccines**

Vol 19 (12) 2020

<https://www.tandfonline.com/toc/ierv20/current>

[Reviewed earlier]

**Gates Open Research**

<https://gatesopenresearch.org/browse/articles>

[Accessed 27 Feb 2021]

[No new digest content identified]

**Genome Medicine**

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 27 Feb 2021]

[No new digest content identified]

## **Global Health Action**

Volume 14, Issue 1 (2021)

<https://www.tandfonline.com/toc/zgha20/current?nav=toCList>

[Reviewed earlier]

## **Global Health: Science and Practice (GHSP)**

Vol. 8, No. 4 December 23, 2020

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

## **Global Public Health**

Volume 16, Issue 3 (2021)

<http://www.tandfonline.com/toc/rgph20/current>

*Article*

### **[COVID-19 vaccines and treatments nationalism: Challenges for low-income countries and the attainment of the SDGs](#)**

Godwell Nhamo, David Chikodzi, Hlengiwe Precious Kunene & Nthivhiseni Mashula

Pages: 319-339

Published online: 15 Dec 2020

*Article*

### **[Acceptability of the human papillomavirus vaccine in schools in Lusaka in Zambia: Role of community and formal health system factors](#)**

Fortress Kucheba, Oliver Mweemba, Tulani Francis L. Matenga & Joseph Mumba Zulu

Pages: 378-389

Published online: 25 Aug 2020

*Article*

### **[Acceptability of the human papillomavirus vaccine in schools in Lusaka in Zambia: Role of community and formal health system factors](#)**

Fortress Kucheba, Oliver Mweemba, Tulani Francis L. Matenga & Joseph Mumba Zulu

Pages: 378-389

Published online: 25 Aug 2020

## **Globalization and Health**

<http://www.globalizationandhealth.com/>

[Accessed 27 Feb 2021]

[No new digest content identified]

## **Health Affairs**

Vol. 40, No. 1 January 2021

<https://www.healthaffairs.org/toc/hlthaff/current>

### ***COVID-19 Response, Medicaid & More***

[Reviewed earlier]

### **Health and Human Rights**

Volume 22, Issue 2, December 2020

<https://www.hhrjournal.org/volume-22-issue-2-december-2020/>

***Special Section: Big Data, Technology, Artificial Intelligence and the Right to Health***

[Reviewed earlier]

### **Health Economics, Policy and Law**

Volume 16 - Special Issue 1 - January 2021

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

***SPECIAL ISSUE: The future of EU health law and policy***

[Reviewed earlier]

### **Health Policy and Planning**

Volume 35, Issue 10, December 2020

<https://academic.oup.com/heapol/issue/35/10>

[Reviewed earlier]

### **Health Research Policy and Systems**

<http://www.health-policy-systems.com/content>

[Accessed 27 Feb 2021]

[No new digest content identified]

### **Human Gene Therapy**

Volume 32, Issue 3-4 / February 2021

<https://www.liebertpub.com/toc/hum/32/3-4>

***Special Issue on Oncolytic Viruses/Cancer Immunotherapy***

[New issue; No digest content identified]

### **Humanitarian Exchange Magazine**

Number 78, October 2020

<https://odihpn.org/magazine/inclusion-of-persons-with-disabilities-in-humanitarian-action-what-now/>

**[Disability inclusion in humanitarian action](#)**

*by HPN October 2020*

The theme of this edition of Humanitarian Exchange, co-edited with Sherin Alsheikh Ahmed from Islamic Relief Worldwide, is disability inclusion in humanitarian action. Persons with disabilities are not only disproportionately impacted by conflicts, disasters and other emergencies, but also face barriers to accessing humanitarian assistance. At the same time, global commitments and standards and the IASC Guidelines on the inclusion of persons with disabilities in humanitarian action all emphasise how persons with disabilities are also active agents of change. Disability and age-focused organisations have led on testing and demonstrating how inclusion can be done better. Yet despite this progress, challenges to effective inclusion remain.

As Kirstin Lange notes in the lead article, chief among these challenges is humanitarian agencies' lack of engagement with organisations of persons with disabilities. Simione Bula, Elizabeth Morgan and Teresa Thomson look at disability inclusion in humanitarian response in the Pacific, and Kathy Al Jubeh and Alradi Abdalla argue for a 'participation revolution', building on learning from the gender movement. Tchaurea Fleury and Sulayman AbdulMumuni Ujah outline how the Bridge Article 11 training initiative is encouraging constructive exchange between humanitarian and disability actors. The lack of good, disaggregated data is highlighted by Sarah Collinson; Frances Hill, Jim Cranshaw and Carys Hughes emphasise the need for training resources in local languages and accessible formats; and Sophie Van Eetvelt and colleagues report on a review of the evidence on inclusion of people with disabilities and older people.

Rebecca Molyneux and co-authors analyse the findings of a review of a DFID programme in north-east Nigeria, while Carolin Funke highlights the importance of strategic partnerships between disability-focused organisations, drawing on her research in Cox's Bazar. Sherin Alsheikh Ahmed describes Islamic Relief Worldwide's approach to mainstreaming protection and inclusion, while Pauline Thivillier and Valentina Shafina outline IRC's Client Responsive Programming. The edition ends with reflections by Mirela Turcanu and Yves Ngunzi Kahashi on CAFOD's SADI approach.

### **Human Vaccines & Immunotherapeutics** (formerly Human Vaccines)

Volume 17, Issue 1, 2021

<https://www.tandfonline.com/toc/khvi20/current>

[Reviewed earlier]

### **Infectious Agents and Cancer**

<http://www.infectagentscancer.com/content>

[Accessed 27 Feb 2021]

[No new digest content identified]

### **Infectious Diseases of Poverty**

<http://www.idpjournal.com/content>

[Accessed 27 Feb 2021]

[No new digest content identified]

### **International Health**

SUPPLEMENT Volume 13, Issue Supplement\_1, January 2021

[https://academic.oup.com/inthealth/issue/13/Supplement\\_1](https://academic.oup.com/inthealth/issue/13/Supplement_1)

***Two Decades of Public Health Achievements in Lymphatic Filariasis (2000–2020): Reflections, Progress and Future Challenges***

[Reviewed earlier]

### **International Journal of Community Medicine and Public Health**

Vol 8, No 1 (2021) January 2021

<https://www.ijcmph.com/index.php/ijcmph/issue/view/72>

*Table of Contents*

[Reviewed earlier]

### **International Journal of Epidemiology**

Volume 49, Issue 6, December 2020

<https://academic.oup.com/ije/issue>

[Reviewed earlier]

### **International Journal of Human Rights in Healthcare**

Volume 14 Issue 1 2021

<https://www.emerald.com/insight/publication/issn/2056-4902/vol/14/iss/1>

*Table of Contents*

[Reviewed earlier]

### **International Journal of Infectious Diseases**

February 2021 Volume 103 p1-654

<https://www.ijidonline.com/current>

[Reviewed earlier]

### **JAMA**

February 23, 2021, Vol 325, No. 8, Pages 705-798

<https://jamanetwork.com/journals/jama/currentissue>

*Research Letter*

#### **[All-Cause Excess Mortality and COVID-19–Related Mortality Among US Adults Aged 25-44 Years, March-July 2020](#)**

Jeremy Samuel Faust, MD, MS; Harlan M. Krumholz, MD, SM; Chengan Du, PhD; et al.

free access has active quiz has multimedia has audio

JAMA. 2021;325(8):785-787. doi:10.1001/jama.2020.24243

This study compares all-cause excess mortality and COVID-19–related mortality during the early pandemic period (March-July 2020) with unintentional drug overdoses, the usual leading cause of death in young adults, during the same period in 2018 among adults aged 25 to 44 years.

*Health Policy*

#### **[Racial and Ethnic Health Disparities Related to COVID-19](#)**

Leo Lopez III, MD, MHS; Louis H. Hart III, MD; Mitchell H. Katz, MD

free access has active quiz has audio

JAMA. 2021;325(8):719-720. doi:10.1001/jama.2020.26443

This Viewpoint reviews data demonstrating worse risk and outcomes for non-White patients with coronavirus disease 2019 (COVID-19) and makes policy proposals to mitigate the disparities, including expansion of Medicaid eligibility to expand health care access, multilingual and culturally appropriate communication and outreach, and easing accessibility to social services through health care contacts to address housing, food, legal, and economic stressors.

## **[A Viral Pandemic, Vaccine Safety, and Compensation for Adverse Events](#)**

H. Cody Meissner, MD

free access

JAMA. 2021;325(8):721-722. doi:10.1001/jama.2020.26792

This Viewpoint reviews the system in place to compensate US residents for proven vaccine injury via the Countermeasures Injury Compensation Program and emphasizes that the benefit of COVID-19 vaccines outweighs any potential harm.

*Editorial*

## **[Reassuring the Public and Clinical Community About the Scientific Review and Approval of a COVID-19 Vaccine](#)**

Howard Bauchner, MD; Preeti N. Malani, MD, MSJ; Joshua Sharfstein, MD

*Clinical Update*

## **[Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine](#)**

Tom Shimabukuro, MD, MPH, MBA; Narayan Nair, MD

free access has active quiz has audio

JAMA. 2021;325(8):780-781. doi:10.1001/jama.2021.0600

This JAMA Insights review provides clinical details of anaphylactic reactions reported to and verified by the CDC in the first week of use of the Pfizer-BioNTech COVID-19 vaccine in the US, December 14-23, 2020.

## **JAMA Network**

### **[COVID-19 Update February 27, 2021](#)**

*These articles on COVID-19 were published across the JAMA Network in the last week.*

## **JAMA Pediatrics**

February 2021, Vol 175, No. 2, Pages 115-216

<http://archpedi.jamanetwork.com/issue.aspx>

[Reviewed earlier]

## **JBI Evidence Synthesis**

February 2021 - Volume 19 - Issue 2

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[New issue; No digest content identified]

## **Journal of Adolescent Health**

March 2021 Volume 68 Issue 3 p429-636

<https://www.jahonline.org/current>

[New issue; No digest content identified]

## **Journal of Artificial Intelligence Research**



Vol. 70 (2021)

<https://www.jair.org/index.php/jair>

[Reviewed earlier]

### **Journal of Community Health**

Volume 46, issue 1, February 2021

<https://link.springer.com/journal/10900/volumes-and-issues/46-1>

[Reviewed earlier]

### **Journal of Development Economics**

Volume 149 March 2021

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/149/suppl/C>

[Reviewed earlier]

### **Journal of Empirical Research on Human Research Ethics**

Volume 15 Issue 5, December 2020

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

### **Journal of Epidemiology & Community Health**

March 2021 - Volume 75 - 3

<https://jech.bmj.com/content/75/3>

[New issue; No digest content identified]

### **Journal of Evidence-Based Medicine**

Volume 14, Issue 1 Pages: 1-81 February 2021

<https://onlinelibrary.wiley.com/toc/17565391/current>

*EDITORIAL*

#### **[Evidence-based Chinese medicine for the response to public health emergencies: The Guangzhou declaration](#)**

Xiaojia Ni et al for the [Evidence-based Traditional and Integrative Medicine Responding to Public Health Emergencies Working Group](#)

Pages: 3-4

First Published: 07 February 2021

*REVIEW*

#### **[Evidence-based traditional Chinese medicine research: Two decades of development, its impact, and breakthrough](#)**

Guihua Tian et al

Pages: 65-74

First Published: 22 February 2021

**Journal of Global Ethics**

Volume 16, Issue 2, 2020

<http://www.tandfonline.com/toc/rjge20/current>

[Reviewed earlier]

**Journal of Health Care for the Poor and Underserved (JHCPU)**

Volume 31, Number 4, November 2020 Supplement

<https://muse.jhu.edu/issue/43320>

*Table of Contents*

[Reviewed earlier]

**Journal of Immigrant and Minority Health**

Volume 23, issue 1, February 2021

<https://link.springer.com/journal/10903/volumes-and-issues/23-1>

[Reviewed earlier]

**Journal of Immigrant & Refugee Studies**

Volume 19, 2021\_ Issue 1

<https://www.tandfonline.com/toc/wimm20/current>

***Current Conflicts over Migration, Belonging and Membership: Classificatory Struggles Revisited***

[Reviewed earlier]

**Journal of Infectious Diseases**

Volume 223, Issue 3, 1 February 2021

<https://academic.oup.com/jid/issue/223/3>

[Reviewed earlier]

**Journal of Medical Ethics**

February 2021 - Volume 47 - 2

<http://jme.bmj.com/content/current>

[Reviewed earlier]

**Journal of Patient-Centered Research and Reviews**

Volume 8, Issue 1 (2021)

<https://digitalrepository.aurorahealthcare.org/jpcrr/>

[Reviewed earlier]

**Journal of Pediatrics**

March 2021 Volume 230 p1-282

<http://www.jpeds.com/current>

[New issue; no digest content identified]

### **Journal of Pharmaceutical Policy and Practice**

<https://joppp.biomedcentral.com/>

[Accessed 27 Feb 2021]

[Reviewed earlier]

### **Journal of Public Health Management & Practice**

March/April 2021 - Volume 27 - Issue 2

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>

[New issue; no digest content identified]

### **Journal of Public Health Policy**

Volume 41, issue 4, December 2020

<https://link.springer.com/journal/41271/volumes-and-issues/41-4>

[Reviewed earlier]

### **Journal of Refugee & Global Health**

Volume 4, Issue 1 (2021)

<https://ir.library.louisville.edu/rgh/>

[Reviewed earlier]

### **Journal of the Royal Society – Interface**

February 2021 Volume 18 Issue 175

<https://royalsocietypublishing.org/toc/rsif/current>

[Reviewed earlier]

### **Journal of Travel Medicine**

Volume 28, Issue 2, March 2021

<https://academic.oup.com/jtm/issue>

*Perspectives*

**[COVID-19 pandemic: it is time to temporarily close places of worship and to suspend religious gatherings](#)**

[Saber Yezli, PhD, Anas Khan, MD](#)

**[The Hajj pilgrimage during the COVID-19 pandemic in 2020: event hosting without the mass gathering](#)**

[Shahul H Ebrahim, MD, PhD, Yusuf Ahmed, BM, MPH, FRCOG, Saleh A Alqahtani, MD, Ziad A Memish, MD, FRCPC](#)

**[SARS-CoV-2 testing to assure safety in air travel](#)**

[Lin H Chen, MD, Robert Steffen, MD](#)

Journal of Travel Medicine, Volume 28, Issue 2, March 2021, taaa241,  
<https://doi.org/10.1093/jtm/taaa241>

To support the resumption of travel, rational and consistent testing and quarantine guidelines will be critical. Uniformity in the documentation of COVID-19 test results and vaccination will also be important. We discuss evidence to support standardized testing and quarantine requirements and propose a strategy to allow ease in travel planning.

Systematic Review

Editor's Choice

**[From hydroxychloroquine to ivermectin: what are the anti-viral properties of anti-parasitic drugs to combat SARS-CoV-2?](#)**

S Rakedzon, MD, A Neuberger, MD, A J Domb, Professor, N Petersiel, MD, E Schwartz

**Journal of Virology**

February 2021; Volume 95, Issue 4

<http://jvi.asm.org/content/current>

[Reviewed earlier]

**The Lancet**

Feb 27, 2021 Volume 397 Number 10276 p767-852, e7

<https://www.thelancet.com/journals/lancet/issue/current>

*Editorial*

**[50 years of the inverse care law](#)**

The Lancet

"The availability of good medical care tends to vary with the need for it in the population served. This inverse care law operates more completely where medical care is most exposed to market forces, and less so where such exposure is reduced."

These understated opening lines of Julian Tudor Hart's paper, The Inverse Care Law, are as relevant now (50 years to the day since publication) as in 1971. The paper is one of the landmark publications in The Lancet's near 200-year history, and the resonance of Tudor Hart's definition of the inverse care law has global and timeless importance. Simply expressed, Tudor Hart observed that disadvantaged populations need more health care than advantaged populations, but receive less...

*Health Policy*

**[The inverse care law re-examined: a global perspective](#)**

Richard Cookson, Tim Doran, Miqdad Asaria, Indrani Gupta, Fiorella Parra Mujica

*Summary*

An inverse care law persists in almost all low-income and middle-income countries, whereby socially disadvantaged people receive less, and lower-quality, health care despite having greater need. By contrast, a disproportionate care law persists in high-income countries, whereby socially disadvantaged people receive more health care, but of worse quality and insufficient quantity to meet their additional needs. Both laws are caused not only by financial barriers and fragmented health insurance systems but also by social inequalities in care seeking and co-investment as well as the costs and benefits of health care. Investing in more integrated universal health coverage and stronger primary care, delivered in proportion to need, can improve population health and reduce health inequality. However, trade-offs sometimes exist between health policy objectives. Health-care technologies, policies, and

resourcing should be subjected to distributional analysis of their equity impacts, to ensure the objective of reducing health inequalities is kept in sight.  
and threaten an upswing in armed conflict.

### **The Lancet Child & Adolescent Health**

Mar 2021 Volume 5 Number 3 p155-232, e6-e8  
<https://www.thelancet.com/journals/lanchi/issue/current>  
[New issue; No digest content identified]

### **Lancet Digital Health**

Mar 2021 Volume 3 Number 3 e135-e203  
<https://www.thelancet.com/journals/landig/issue/current>  
*Health Policy*

#### **[Approval of artificial intelligence and machine learning-based medical devices in the USA and Europe \(2015–20\): a comparative analysis](#)**

Urs J Muehlematter, Paola Daniore, Kerstin N Vokinger

##### *Summary*

There has been a surge of interest in artificial intelligence and machine learning (AI/ML)-based medical devices. However, it is poorly understood how and which AI/ML-based medical devices have been approved in the USA and Europe. We searched governmental and non-governmental databases to identify 222 devices approved in the USA and 240 devices in Europe. The number of approved AI/ML-based devices has increased substantially since 2015, with many being approved for use in radiology. However, few were qualified as high-risk devices. Of the 124 AI/ML-based devices commonly approved in the USA and Europe, 80 were first approved in Europe. One possible reason for approval in Europe before the USA might be the potentially relatively less rigorous evaluation of medical devices in Europe. The substantial number of approved devices highlight the need to ensure rigorous regulation of these devices. Currently, there is no specific regulatory pathway for AI/ML-based medical devices in the USA or Europe. We recommend more transparency on how devices are regulated and approved to enable and improve public trust, efficacy, safety, and quality of AI/ML-based medical devices. A comprehensive, publicly accessible database with device details for Conformité Européene (CE)-marked medical devices in Europe and US Food and Drug Administration approved devices is needed.

### **Lancet Global Health**

Mar 2021 Volume 9 Number 3 e218-e371  
<https://www.thelancet.com/journals/langlo/issue/current>  
*Editorial*

#### **[Breaking the inverse care law](#)**

The Lancet Global Health

##### *Comment*

#### **[Measles: the long walk to elimination drawn out by COVID-19](#)**

Etienne Gignoux, Linda Ezzo, Yap Boum

##### *Articles*

**[A scorecard of progress towards measles elimination in 15 west African countries, 2001–19: a retrospective, multicountry analysis of national immunisation coverage and surveillance data](#)**

Oghenebrume Wariri, et al.

**Lancet Infectious Diseases**

Mar 2021 Volume 21 Number 3 p297-438, e36-e63

<https://www.thelancet.com/journals/laninf/issue/current>

*Editorial*

**[The COVID-19 exit strategy—why we need to aim low](#)**

The Lancet Infectious Diseases

*Comment*

**[Direct effects of pneumococcal conjugate vaccines among children in Latin America and the Caribbean](#)**

Cynthia G Whitney, Cristiana M Toscano

*Articles*

**[The direct effect of pneumococcal conjugate vaccines on invasive pneumococcal disease in children in the Latin American and Caribbean region \(SIREVA 2006–17\): a multicentre, retrospective observational study](#)**

Clara Inés Agudelo, et al. and the the SIREVA Working Group

*Scoping Review*

**[Highly targeted spatiotemporal interventions against cholera epidemics, 2000–19: a scoping review](#)**

Ruwan Ratnayake, et al

*Personal View*

**[The scientific and ethical feasibility of immunity passports](#)**

Rebecca C H Brown, Dominic Kelly, Dominic Wilkinson, Julian Savulescu

*Summary*

There is much debate about the use of immunity passports in the response to the COVID-19 pandemic. Some have argued that immunity passports are unethical and impractical, pointing to uncertainties relating to COVID-19 immunity, issues with testing, perverse incentives, doubtful economic benefits, privacy concerns, and the risk of discriminatory effects. We first review the scientific feasibility of immunity passports. Considerable hurdles remain, but increasing understanding of the neutralising antibody response to COVID-19 might make identifying members of the community at low risk of contracting and transmitting COVID-19 possible. We respond to the ethical arguments against immunity passports and give the positive ethical arguments. First, a strong presumption should be in favour of preserving people's free movement if at all feasible. Second, failing to recognise the reduced infection threat immune individuals pose risks punishing people for low-risk behaviour. Finally, further individual and social benefits are likely to accrue from allowing people to engage in free movement. Challenges relating to the implementation of immunity passports ought to be met with targeted solutions so as to maximise their benefit.

**Lancet Public Health**

Mar 2021 Volume 6 Number 3 e136-e191

<https://www.thelancet.com/journals/lanpub/issue/current>

[New issue; No digest content identified]

**Lancet Respiratory Medicine**

Feb 2021 Volume 9 Number 2 p117-216, e11-e21

<https://www.thelancet.com/journals/lanres/issue/current>

[Reviewed earlier]

**Maternal and Child Health Journal**

Volume 25, issue 2, February 2021

<https://link.springer.com/journal/10995/volumes-and-issues/25-2>

[Reviewed earlier]

**Medical Decision Making (MDM)**

Volume 41 Issue 2, February 2021

<http://mdm.sagepub.com/content/current>

[Reviewed earlier]

**The Milbank Quarterly**

*A Multidisciplinary Journal of Population Health and Health Policy*

Volume 98, Issue 4 Pages: 1021-1341, E1-E12 December 2020

<https://onlinelibrary.wiley.com/toc/14680009/current>

[Reviewed earlier]

**Nature**

Volume 590 Issue 7846, 18 February 2021

[http://www.nature.com/nature/current\\_issue.html](http://www.nature.com/nature/current_issue.html)

[Reviewed earlier]

**Nature Biotechnology**

Volume 39 Issue 2, February 2021

<https://www.nature.com/nbt/volumes/39/issues/2>

[Reviewed earlier]

**Nature Communications**

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 27 Feb 2021)

[No new digest content identified]

### **Nature Genetics**

Volume 53 Issue 2, February 2021

<https://www.nature.com/ng/volumes/53/issues/2>

[Reviewed earlier]

### **Nature Human Behaviour**

Volume 5 Issue 2, February 2021

<https://www.nature.com/nathumbehav/volumes/5/issues/2>

[Reviewed earlier]

### **Nature Medicine**

Volume 27 Issue 2, February 2021

<https://www.nature.com/nm/volumes/27/issues/2>

[Reviewed earlier]

### **Nature Reviews Genetics**

Volume 22 Issue 3, March 2021

<https://www.nature.com/nrg/volumes/22/issues/3>

#### **Review Article | 04 December 2020**

#### **[Host genetics and infectious disease: new tools, insights and translational opportunities](#)**

Infectious diseases are an ever-present global threat. In this Review, Kwok, Mentzer and Knight discuss our latest understanding of how human genetics influence susceptibility to disease. Furthermore, they discuss emerging progress in the interplay between host and pathogen genetics, molecular responses to infection and vaccination, and opportunities to bring these aspects together for rapid responses to emerging diseases such as COVID-19.

Andrew J. Kwok, Alex Mentzer & Julian C. Knight

### **Nature Reviews Immunology**

Volume 21 Issue 2, February 2021

<https://www.nature.com/nri/volumes/21/issues/2>

[Reviewed earlier]

### **Nature Reviews Drug Discovery**

Volume 20 Issue 2, February 2021

<https://www.nature.com/nrd/volumes/20/issues/2>

[Reviewed earlier]

### **New England Journal of Medicine**

February 25, 2021 Vol. 384 No. 8

<http://www.nejm.org/toc/nejm/medical-journal>

*Perspective*



## **Last-Mile Logistics of Covid Vaccination — The Role of Health Care Organizations**

Thomas H. Lee, M.D., and Alice H. Chen, M.D., M.P.H.

*Editorial*

### **Research in the Context of a Pandemic**

H. Clifford Lane, M.D., and Anthony S. Fauci, M.D.

The current literature on the treatment of coronavirus disease 2019 (Covid-19) is filled with anecdotal reports of therapeutic successes in clinical trials with small numbers of patients and observational cohort studies claiming efficacy with little regard to the effect of unrecognized confounders. For the field to move forward and for patients' outcomes to improve, there will need to be fewer small or inconclusive studies and more studies such as the dexamethasone trial now reported by the RECOVERY Collaborative Group<sup>1</sup> in this issue of the Journal...

*Editorial*

### **The RECOVERY Platform**

Sharon-Lise T. Normand, Ph.D.

## **Pediatrics**

Vol. 147, Issue 2 1 Feb 2021

<https://pediatrics.aappublications.org/>

[Reviewed earlier]

## **PharmacoEconomics**

Volume 39, issue 3, March 2021

<https://link.springer.com/journal/40273/volumes-and-issues/39-3>

*Commentary*

### **Productivity-Adjusted Life-Years: A New Metric for Quantifying Disease Burden**

Zanfina Ademi, Ilana N. Ackerman, Danny Liew

Published: 11 January 2021

### **Assessment of the Effects of Active Immunisation against Respiratory Syncytial Virus (RSV) using Decision-Analytic Models: A Systematic Review with a Focus on Vaccination Strategies, Modelling Methods and Input Data**

Marina Treskova, Francisco Pozo-Martin, Thomas Harder,

Content type: Systematic Review

Published: 19 January 2021

## **PLoS Genetics**

<https://journals.plos.org/plosgenetics/>

(Accessed 27 Feb 2021)

[No new digest content identified]

## **PLoS Medicine**

<http://www.plosmedicine.org/>

(Accessed 27 Feb 2021)  
[No new digest content identified]

### **PLoS Neglected Tropical Diseases**

<http://www.plosntds.org/>

(Accessed 27 Feb 2021)  
[No new digest content identified]

### **PLoS One**

<http://www.plosone.org/>

[Accessed 27 Feb 2021]

#### **[Impact of pneumococcal conjugate vaccine on invasive pneumococcal disease in children under 5 years of age in the Czech Republic](#)**

Jana Kozakova, Pavla Krizova, Marek Maly  
Research Article | published 26 Feb 2021 PLOS ONE  
<https://doi.org/10.1371/journal.pone.0247862>

#### **[Implementing WHO guidance on conducting and analysing vaccination coverage cluster surveys: Two examples from Nigeria](#)**

John Ndegwa Wagai, Dale Rhoda, Mary Prier, Mary Kay Trimmer, Caitlin B. Clary, Joseph Oteri, Bassey Okposen, Adeyemi Adeniran, Carolina Danovaro-Holliday, Felicity Cutts  
Research Article | published 26 Feb 2021 PLOS ONE  
<https://doi.org/10.1371/journal.pone.0247415>

#### **[Knowledge, attitude and practice of vaccinators and vaccine handlers on vaccine cold chain management in public health facilities, Ethiopia: Cross-sectional study](#)**

Solomon Ahmed Mohammed, Birhanu Demeke Workneh, Mesfin Haile kahissay  
Research Article | published 25 Feb 2021 PLOS ONE  
<https://doi.org/10.1371/journal.pone.0247459>

### **PLoS Pathogens**

<http://journals.plos.org/plospathogens/>

[Accessed 27 Feb 2021]  
[No new digest content identified]

### **PNAS - Proceedings of the National Academy of Sciences of the United States of America**

February 23, 2021; vol. 118 no. 8  
<https://www.pnas.org/content/118/8>  
[New issue: No digest content identified]

### **Prehospital & Disaster Medicine**

Volume 36 - Issue 1 - February 2021

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>  
[Reviewed earlier]

### **Preventive Medicine**

Volume 143 February 2021

<https://www.sciencedirect.com/journal/preventive-medicine/vol/143/suppl/C>

[Reviewed earlier]

### **Proceedings of the Royal Society B**

24 February 2021 Volume 288 Issue 1945

<https://royalsocietypublishing.org/toc/rspb/current>

[New issue: No digest content identified]

### **Public Health**

Volume 190 Pages e1-e30, 1-176 (January 2021)

<https://www.sciencedirect.com/journal/public-health/vol/190/suppl/C>

[Reviewed earlier]

### **Public Health Ethics**

Volume 13, Issue 3, November 2020

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

### **Public Health Reports**

Volume 136 Issue 2, March/April 2021

<https://journals.sagepub.com/toc/phrg/136/2>

[New issue: No digest content identified]

### **Qualitative Health Research**

Volume 31 Issue 4, March 2021

<http://qhr.sagepub.com/content/current>

[New issue: No digest content identified]

### **Research Ethics**

Volume 17 Issue 1, January 2021

<http://journals.sagepub.com/toc/reab/current>

[Reviewed earlier]

### **Reproductive Health**

<http://www.reproductive-health-journal.com/content>

[Accessed 27 Feb 2021]  
[No new digest content identified]

**Revista Panamericana de Salud Pública/Pan American Journal of Public Health  
(RPSP/PAJPH)**

<https://www.paho.org/journal/en>

*Selected Articles*

26 Feb 2021

**[National Network for Knowledge Management, Research, and Innovation in Tuberculosis in Colombia](#)**

Current topic | Spanish |

26 Feb 2021

**[Diagnostic properties of case definitions of suspected COVID-19 in Chile, 2020](#)**

Original research | Spanish |

**Risk Analysis**

Volume 41, Issue 2 Pages: 223-406 February 2021

<https://onlinelibrary.wiley.com/toc/15396924/current>

***Special Issue: Global Poliovirus Risk Management and Modeling***

[Reviewed earlier]

**Risk Management and Healthcare Policy**

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 27 Feb 2021]

[No new digest content identified]

**Science**

26 February 2021 Vol 371, Issue 6532

<http://www.sciencemag.org/current.dtl>

*Policy Forum*

**[Optimizing age-specific vaccination](#)**

By Meagan C. Fitzpatrick, Alison P. Galvani

Science 26 Feb 2021 : 890-891 Full Access

*Vaccination strategies are not one-size-fits-all*

*Summary*

Efficacious vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed, tested, and approved for emergency use with unprecedented speed. Deployment of multiple vaccines was initiated in several countries less than 1 year after identification of the virus. Although vaccine production is being rapidly scaled up, demand will exceed supply for the next several months. Consequently, an urgent challenge is the optimization of vaccine allocation to maximize public health benefit. On page 916 of this issue, Bubar et al. (1) demonstrate that vaccination of older people is the optimal age-based strategy to alleviate the burden of COVID-19. Although vaccination of younger adults is projected to avert the greatest incidence, vaccinating older adults will most effectively reduce

mortality. In addition, they assess targeted vaccination that was based on serological status, finding that vaccinating seronegative individuals improves efficiency especially in settings where seroprevalence is high.

*Report*

**[Model-informed COVID-19 vaccine prioritization strategies by age and serostatus](#)**

By Kate M. Bubar, Kyle Reinholt, Stephen M. Kissler, Marc Lipsitch, Sarah Cobey, Yonatan H. Grad, Daniel B. Larremore

Science 26 Feb 2021 : 916-921 Open Access

To minimize mortality, vaccinate seronegative persons most at risk of death: those with comorbidities and those 60+ years of age.

**Science Translational Medicine**

24 February 2021 Vol 13, Issue 582

<https://stm.sciencemag.org/>

[New issue; No digest content identified]

**Social Science & Medicine**

Volume 270 February 2021

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/270/suppl/C>

[Reviewed earlier]

**Systematic Reviews**

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 27 Feb 2021]

<https://stm.sciencemag.org/>

[No new digest content identified]

**Theoretical Medicine and Bioethics**

Volume 41, issue 4, August 2020

<https://link.springer.com/journal/11017/volumes-and-issues/41-4>

***Special Issue: Philosophical investigations into the essence of pediatric suffering***

[Reviewed earlier]

**Travel Medicine and Infectious Diseases**

Volume 39 January–February 2021

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/39/suppl/C>

[Reviewed earlier]

**Tropical Medicine & International Health**

Volume 26, Issue 2 Pages: i-iv, 121-255 February 2021

<https://onlinelibrary.wiley.com/toc/13653156/current>

[Reviewed earlier]

## **Vaccine**

Volume 39, Issue 10 Pages 1473-1546 (5 March 2021)

<https://www.sciencedirect.com/journal/vaccine/vol/39/issue/10>

*Research article Abstract only*

### **[Effectiveness of the live-attenuated herpes zoster vaccine 2 years after its introduction in Australia](#)**

Jialing Lin, Timothy Dobbins, James G. Wood, Carla Bernardo, ... Bette Liu

Pages 1493-1498

*Research article Abstract only*

### **[Social amplification of risk and “probable vaccine damage”: A typology of vaccination beliefs in 28 European countries](#)**

Simona - Nicoleta Vulpe, Cosima Rughinis

Pages 1508-1515

*Research article Abstract only*

### **[Formative research to address vaccine hesitancy in Tajikistan](#)**

Ann Carroll Klassen, Brandy-Joe Milliron, Leslie Reynolds, Zubayda Bakhtibekova, ... Bridget Job-Johnson

Pages 1516-1527

## **Vaccines — Open Access Journal**

<http://www.mdpi.com/journal/vaccines>

(Accessed 27 Feb 2021)

*Open Access Review*

### **[Internal and External Validity of Social Media and Mobile Technology-Driven HPV Vaccination Interventions: Systematic Review Using the Reach, Effectiveness, Adoption, Implementation, Maintenance \(RE-AIM\) Framework](#)**

by [Matthew Asare](#), [Braden Popelsky](#), [Emmanuel Akowuah](#), [Beth A. Lanning](#) and [Jane R. Montealegre](#)  
Vaccines 2021, 9(3), 197; <https://doi.org/10.3390/vaccines9030197> - 26 Feb 2021

*Abstract*

Social media human papillomavirus (HPV) vaccination interventions show promise for increasing HPV vaccination rates. An important consideration for the implementation of effective interventions into real-world practice is the translation potential, or external validity, of the intervention. To this end, we conducted a systematic [...]

*Open Access Article*

### **[Who Should Get COVID-19 Vaccine First? A Survey to Evaluate Hospital Workers' Opinion](#)**

by [Lucia Craxì](#), [Alessandra Casuccio](#), [Emanuele Amodio](#) and [Vincenzo Restivo](#)

Vaccines 2021, 9(3), 189; <https://doi.org/10.3390/vaccines9030189> - 25 Feb 2021

*Abstract*

Prospective planning of COVID-19 vaccines allocation will be essential to maximize public health and societal benefits while preserving equity. Decisions about how to allocate limited supplies of vaccines need to be clear about the criteria used in setting priorities, with a specific commitment [...]

Open Access Article

**Public Health and Economic Benefits of Influenza Vaccination of the Population Aged 50 to 59 Years without Risk Factors for Influenza Complications in Mexico: A Cross-Sectional Epidemiological Study**

by Miguel Betancourt-Cravioto, Jorge Abelardo Falcón-Lezama, Rodrigo Saucedo-Martínez, Myrna María Alfaro-Cortés and Roberto Tapia-Conyer

Vaccines 2021, 9(3), 188; <https://doi.org/10.3390/vaccines9030188> - 24 Feb 2021

*Abstract*

The Mexican influenza vaccination program does not include a recommendation for people aged 50–59 years without risk factors for influenza complications, and there are limited data regarding the cost-effectiveness of vaccinating this population. To explore the clinical and economic effects of including this [...]

**Value in Health**

February 2021 Volume 24 Issue 2 p145-312

<https://www.valueinhealthjournal.com/current>

**THEMED SECTION: OPIOID MISUSE: A GLOBAL CRISIS**

[Reviewed earlier]

\*

\*

\*

\*

**Media/Policy Watch**

This watch section is intended to alert readers to substantive news, analysis and opinion from the general media and selected think tanks and similar organizations on vaccines, immunization, global public health and related themes. *Media Watch* is not intended to be exhaustive, but indicative of themes and issues CVEP is actively tracking. This section will grow from an initial base of newspapers, magazines and blog sources, and is segregated from *Journal Watch* above which scans the peer-reviewed journal ecology.

We acknowledge the Western/Northern bias in this initial selection of titles and invite suggestions for expanded coverage. We are conservative in our outlook in adding news sources which largely report on primary content we are already covering above. Many electronic media sources have tiered, fee-based subscription models for access. We will provide full-text where content is published without restriction, but most publications require registration and some subscription level.

**The Atlantic**

<http://www.theatlantic.com/magazine/>

Accessed 27 Feb 2021

*Ideas*

**Overcaution Carries Its Own Danger to Children**

*Incessant pessimism about the coronavirus is hard to kick, but the vaccines are banishing any doubt about reopening schools.*

27 Feb 2021

Monica Gandhi, Professor of medicine at UCSF

## **BBC**

<http://www.bbc.co.uk/>

*Accessed 27 Feb 2021*

[No new, unique, relevant content]

## **The Economist**

<http://www.economist.com/>

*Accessed 27 Feb 2021*

Feb 27th 2021

*The Economist explains*

### **[Is SARS-CoV-2 evolving to become more lethal?](#)**

Most viruses become less deadly as they mutate. This one may be different

## **Financial Times**

<https://www.ft.com/>

*Accessed 27 Feb 2021*

*Coronavirus:*

### **[Ecuador's health minister quits over handling of pandemic](#)**

February 26, 2021

*Melinda Mills*

### **[Vaccine passports are a technical and ethical minefield](#)**

February 26, 2021

*Coronavirus:*

### **[Chinese jabs arrive in Argentina as 'vaccine diplomacy' grows](#)**

February 26, 2021

### **[Africa will pay more for Russian Covid vaccine than 'western' jabs](#)**

...The African Union will pay three times more for Russia's Sputnik V jab than it is paying for the Oxford/AstraZeneca and Novavax vaccines, according to people familiar with the procurement process. The...

February 25, 2021

## **Forbes**

<http://www.forbes.com/>

*Accessed 27 Feb 2021*

Feb 27, 2021

### **[There Are Libertarians In A Pandemic, And For Good Reason](#)**

Someday, when people compile the definitive documents about the Covid-19 pandemic, I hope his work gets a special place—particularly his post "Free Market Vaccines," which was later revised and published by National Review (I have previously used Cochrane's post here and here).

By [Art Carden](#) Contributor

## **Foreign Affairs**

<http://www.foreignaffairs.com/>

*Accessed 27 Feb 2021*

### **[China Must Stop Hiding Its Vaccine Data](#)**



*Beijing Is Undermining Confidence in a Vaccine the World Desperately Needs*  
By Eyck Freymann and Justin Stebbing  
February 26, 2021

### **Foreign Policy**

<http://foreignpolicy.com/>

*Accessed 27 Feb 2021*

#### **Doctors Struggle to Convince Pakistanis to Get Their Vaccine Shot**

The country has too few shots, a stubborn public, and little experience—but the program may still work.

Argument | Jalal Baig

#### **Don't Let Drug Companies Create a System of Vaccine Apartheid**

To avoid repeating the pitfalls of the HIV/AIDS crisis, governments and the WTO must make COVID-19 vaccination a public good by temporarily waiving intellectual property rights and compelling emergency production.

Argument | Fatima Hassan

### **The Guardian**

<http://www.guardiannews.com/>

*Accessed 27 Feb 2021*

[No new, unique, relevant content]

### **New Yorker**

<http://www.newyorker.com/>

*Accessed 27 Feb 2021*

[No new, unique, relevant content]

### **New York Times**

<http://www.nytimes.com/>

*Accessed 27 Feb 2021*

*Middle East*

#### **Palestinians Go Into New Lockdown While Awaiting Vaccines**

Covid cases are surging again in the West Bank amid a dispute over Israel's obligations toward the Palestinians in the occupied territories.

By Isabel Kershner

PRINT EDITION February 28, 2021

*Politics*

#### **Younger Military Personnel Reject Vaccine, in Warning for Commanders and the Nation**

About one-third of the troops have declined to take the vaccine. Many say they worry the vaccines are unsafe or were developed too quickly. Others want a sense of independence, even in uniform.

By Jennifer Steinhauer

PRINT EDITION February 28, 2021

*Europe*

#### **Amid Slow Vaccine Deliveries, Desperate E.U. Nations Hunt for More**

Countries eager to augment the troubled E.U. buying program are eyeing offers from each other, from Russia and China, and from private brokers, some of whom are fraudsters.

By Matina Stevis-Gridneff

PRINT EDITION Desperate E.U. Nations Hunt for Vaccine Supply | February 27, 2021, Page A4

*Magazine - Americas*

### **'V.I.P. Immunization' for the Powerful and Their Cronies Rattles South America**

A wave of corruption scandals is exposing how the powerful and well-connected in South America jumped the line to get vaccines early. Public dismay is turning into anger.

By Mitra Taj, Anatoly Kurmanaev, Manuela Andreoni and Daniel Politi

PRINT EDITION Fury as V.I.P.s Cut Line For Their Inoculations| February 26, 2021, Page A1

### **Washington Post**

<https://www.washingtonpost.com/>

*Accessed 27 Feb 2021*

### **Texas vaccination site turned away undocumented immigrants over their status, against state policy**

Andrea Salcedo · Morning Mix · Feb 26, 2021

### **Mexico is vaccinating its poorest citizens first — against the advice of health experts**

Kevin Sieff and Paulina Villegas · Feb 26, 2021

### **Vaccination 'passports' may open society, but inequity looms**

Feb 26, 2021

\* \* \* \*

### **Think Tanks et al**

### **Brookings**

<http://www.brookings.edu/>

*Accessed 27 Feb 2021*

*TechStream*

### **How to build more equitable vaccine distribution technology**

Laura Moy and Yael Cannon

Tuesday, February 23, 2021

### **Center for Global Development** [to 27 Feb 2021]

<http://www.cgdev.org/page/press-center>

*Publication*

February 23, 2021

### **Who Gets a COVID-19 Vaccine and Who Pays? The Need for Economic Analysis**

In 2020, epidemiological modelling went from relative obscurity to being central in helping governments, and the public, understand COVID-19 as it spread around the world. In 2021, with the emergence of effective COVID-19 vaccines, Health Technology Assessment (HTA) will be critical to making the best possible decisions in bringing the pandemic under control, particularly in low-and

middle-income countries (LMICs). In this blog we look at the potential of HTA to inform how much vaccine countries should buy, who should pay, and how vaccines can be most effectively delivered.  
Tom Drake et al.

February 23, 2021

### **[How an Allocation of IMF SDRs To Africa Could Be Supported by A Multilateral Reallocation Initiative](#)**

A general SDR allocation has the potential to provide rapidly additional liquidity to African economies, thereby enhancing prospects for crisis mitigation and recovery.

Daouda Sembene

**Chatham House** [to 27 Feb 2021]

<https://www.chathamhouse.org/>

*Accessed 27 Feb 2021*

### **[Beijing's Vaccine Diplomacy Goes Beyond Political Rivalry](#)**

China has been accused of using its vaccine to expand its influence, but for many struggling economies it is filling a gap left by Western states and donors.

*Expert Comment*

22 February 2021

Tin Hinane El Kadi Associate Fellow, Middle East and North Africa Programme

Sophie Zinser Schwarzman Academy Fellow, Asia-Pacific Programme, Middle East North Africa (MENAP) Programme

**CSIS**

<https://www.csis.org/>

*Accessed 27 Feb 2021*

Upcoming Event

### **[A Conversation with Dr. Anthony Fauci and Professor Paul Kelly](#)**

March 9, 2021

**Council on Foreign Relations**

<http://www.cfr.org/>

*Accessed 27 Feb 2021*

*Pharmaceuticals and Vaccines*

### **[What to Know About the Global COVID-19 Vaccine Rollout So Far](#)**

Several countries stand out for their success in delivering coronavirus vaccinations, while most of the world is struggling to figure out how to get immunizations into more arms.

In Brief by Claire Felter

**Kaiser Family Foundation**

[https://www.kff.org/search/?post\\_type=press-release](https://www.kff.org/search/?post_type=press-release)

*Accessed 27 Feb 2021*

February 26, 2021 *News Release*

**Most Americans Now Say They've Gotten At Least One Dose of a COVID-19 Vaccine or Want to Get Vaccinated As Soon As Possible, with Enthusiasm Rising Across Racial, Ethnic and Partisan Groups**

While Enthusiasm Rises, a Persistent Minority Say They Definitely Will Not Get Vaccinated; Republicans, Rural Residents, and Essential Workers Outside Health Care Are Most Reluctant Groups More than half of Americans (55%) now say they want to get vaccinated as soon as possible (37%) or have already received at least...

February 26, 2021 *News Release*

**States Have Made Progress in Vaccinating Older Adults Against COVID-19 in Recent Weeks, But No State Has Vaccinated At Least Half of its Older Population**

Twenty-two states and the District of Columbia have vaccinated at least one-third of their residents who are 65 and older against COVID-19, an updated KFF analysis finds, but no state has crossed the threshold of vaccinating 50 percent or more of its older population. The share of adults 65 and older...

February 24, 2021 *News Release*

**COVID-19 Cases and Deaths Among Nursing Home Residents Have Declined Markedly Following the Introduction of Vaccines**

The number of residents contracting and dying of COVID-19 in nursing homes has declined markedly following the introduction of vaccination efforts in long-term care facilities, a KFF analysis finds. Resident deaths from COVID-19 in nursing homes have decreased by two-thirds (66%) since vaccination efforts began in late December. New cases...

**World Economic Forum** [to 27 Feb 2021]

<https://agenda.weforum.org/news/>

*Media*

[No new relevant content]

\* \* \* \* \*  
\* \* \* \* \*

***Vaccines and Global Health: The Week in Review*** is a service of the Center for Vaccine Ethics and Policy (CVEP)/GE2P2 Global, which is solely responsible for its content, and is an open access publication, subject to the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by-nc/3.0/>). Copyright is retained by CVEP.

*CVEP is a program of the GE2P2 Global Foundation – whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.*

*Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute, PATH, and industry resource members Janssen/J&J, Pfizer and Takeda, (list in formation).*

*Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.*

\* \* \* \* \*  
\* \* \* \* \*